Browse By Person: O'Byrne, Ken

Barr, Martin P., Gray, Steven G., Gately, Kathy, Hams, Emily, Fallon, Padraic G., Davies, Anthony Mitchell, et al. (2020) Correction to: Vascular endothelial growth factor is an autocrine growth factor, signaling through neuropilin-1 in non-small cell lung cancer. Molecular Cancer, 19, Article number: 16 1-2.

8

Rajapakse, Aleksandra, Suraweera, Amila, Boucher, Didier, Jaffary, Syed Ali Naqi Raza, O'Byrne, Ken, Richard, Derek, et al. (2020) Redox regulation in the base excision repair pathway: Old and new players as cancer therapeutic targets. Current Medicinal Chemistry, 27(12), pp. 1901-1921.

Zhou, Jian, Kulasinghe, Arutha, Bogseth, Amanda, O'Byrne, Ken, Punyadeera, Chamindie, & Papautsky, Ian (2019) Isolation of circulating tumor cells in non-small-cell-lung-cancer patients using a multi-flow microfluidic channel. Microsystems and Nanoengineering, 5(1), Article number: 8 1-12.

42

14

10

O'Leary, Connor Gerard, Andelkovic, Vladamir, Ladwa, Rahul, Pavlakis, Nick, Zhou, Caicun, Hirsch, Fred, et al. (2019) Targeting BRAF mutations in non-small cell lung cancer. Translational Lung Cancer Research, 8(6), pp. 1119-1124.

23

1

Ryan, Sarah-Louise, Beard, Sam, Barr, Martin P., Umezawa, Kazou, Heavey, Susan, Godwin, Peter, et al. (2019) Targeting NF-κB-Mediated inflammatory pathways in cisplatin-resistant NSCLC. Lung Cancer, 135, pp. 217-227.

Kulasinghe, Arutha, Kapeleris, Joanna, Kenny, Liz, Warkiani, Majid, Vela, Ian, Thiery, Jean-Paul, et al. (2019) Isolation, characterization and expansion of circulating tumor cells in solid cancers. Cancer Research, 79(13 Supp), Article number: Abstract 1333 1333.

Schuler, Martin, Tan, Eng-Huat, O'Byrne, Ken, Zhang, Li, Boyer, Michael, Mok, Tony, et al. (2019) First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression. Journal of Cancer Research and Clinical Oncology, 145(6), pp. 1569-1579.

41

4

Park, Keunchil, Bennouna, Jaafar, Boyer, Michael, Hida, Toyoaki, Hirsh, Vera, Kato, Terufumi, et al. (2019) Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer. Lung Cancer, 132, pp. 126-131.

31

6

4

O'Leary, Connor Gerard, Xu, Wen, Pavlakis, Nick, Richard, Derek, & O'Byrne, Ken (2019) Rearranged during transfection fusions in non-small cell lung cancer. Cancers, 11(5), Article number: 620 1-6.

40

3

1

Gaule, Patricia, Mukherjee, Nupur, Corkery, Brendan, Eustace, Alex, Gately, Kathy, Roche, Sandra, et al. (2019) Dasatinib treatment increases sensitivity to c-Met inhibition in triple-negative breast cancer cells. Cancers, 11(4), Article number: 548 1-13.

31

2

Kulasinghe, Arutha, Kapeleris, Joanna, Cooper, Carolina, Ebrahimi Warkiani, Majid, O'Byrne, Ken, & Punyadeera, Chamindie (2019) Phenotypic characterization of circulating lung cancer cells for clinically actionable targets. Cancers, 11(3), Article number: 380 1-14.

41

7

5

Adams, M., Burgess, J., Richard, D., & O?Byrne, K. (2019) Enhancing sensitivity to platinum-based therapy by suppressing the novel prognostic factor CDCA3 in non- small cell lung cancer. In 17th Annual British Thoracic Oncology Group Conference (BTOG 2019), 2019-01-23 - 2019-01-25.

Croft, Laura, Mulders, Jaimie, Richard, Derek, & O'Byrne, Ken (2019) Digital holographic imaging as a method for quantitative, live cell imaging of drug response to novel targeted cancer therapies. Methods in Molecular Biology, 2054, pp. 171-183.

1

Suraweera, A., Adams, M., Richard, D., & O?Byrne, K. (2019) Defining COMMD4 as an anti-cancer therapeutic target and potential diagnostic biomarker in lung cancer. In 17th Annual British Thoracic Oncology Group Conference 2019, 2019-01-23 - 2019-01-25.

37

Boucher, D., Ashton, N., Suraweera, A., Burgess, J., Bolderson, E., Barr, M., et al. (2019) Human single-stranded DNA protein 1 (hSSB1): A new prognostic tool and target for non-small cell lung cancer treatment. In 17th Annual British Thoracic Oncology Group Conference 2019, 2019-01-23 - 2019-01-25.

36

Plowman, J., Bolderson, E., Burgess, J., Richard, D., & O?Byrne, K. (2019) Banf1 as a marker of lung cancer cell sensitivity to cisplatin. In 17th Annual British Thoracic Oncology Group Conference (BTOG 2019), 2019-01-23 - 2019-01-25.

33

Bolderson, Emma, Burgess, Joshua, Li, Jun, Gandhi, Neha S., Boucher, Didier, Croft, Laura, et al. (2019) Barrier-to-autointegration factor 1 (Banf1) regulates poly [ADP-ribose] polymerase 1 (PARP1) activity following oxidative DNA damage. Nature Communications, 10(1), Article number: 5501 1-12.

21

Burgess, J., Bolderson, E., Adams, M., Zhang, S., Fox, S., Wright, G., et al. (2019) Chloropyramine increases NSCLC sensitivity to cisplatin in a SASH1 dependent manner. In 17th Annual British Thoracic Oncology Group Conference (BTOG 2019), 2019-01-23 - 2019-01-25.

Boucher, D., Ashton, N., Suraweera, A., Burgess, J., Bolderson, E., Barr, M., et al. (2019) Human single-stranded DNA protein 1 (hSSB1): A prognostic factor and target for non-small cell lung cancer (NSCLC) treatment. In 17th Annual British Thoracic Oncology Group Conference 2019, 2019-01-23 - 2019-01-25.

34

Reck, Martin, Borghaei, Hossein, & O'Byrne, Kenneth J. (2019) Nivolumab plus ipilimumab in non-small-cell lung cancer. Future Oncology, 15(19), pp. 2287-2302.

50

2

Hochmair, M., Cufer, T., Morabito, A., Hao, D., Ta Yang, C., Soo, R., et al. (2019) Sequential treatment with afatinib and osimertinib in real-world patients with EGFR mutation-positive advanced NSCLC: the GioTag study. In 17th Annual British Thoracic Oncology Group Conference (BTOG 2019), 2019-01-23 - 2019-01-25.

36

Baird, Anne-Marie, Easty, David, Jarzabek, Monika, Shiels, Liam, Soltermann, Alex, Klebe, Sonja, et al. (2019) When RON MET TAM in mesothelioma: All druggable for one, and one drug for all? Frontiers in Endocrinology, 10, Article number: 89 1-19.

34

Kulasinghe, Arutha, Perry, Chris, Kenny, Liz, Blick, Tony, Warkiani, Majid E., Vela, Ian, et al. (2018) Circulating tumor cells: The tumor trail left in the blood. In American Association for Cancer Research Annual Meeting (AACR 2018), 2018-04-14 - 2018-04-18.

Moore, G., Heavey, S., O?Byrne, K., Cuffe, S., Finn, S.P., O?Neill, M., et al. (2018) Activated cMyc/PIM kinase promotes resistance to PI3K/mTOR inhibition in NSCLC. In 16th Annual British Thoracic Oncology Group Conference (BTOG 2018), 2018-01-24 - 2018-01-26.

29

Wu, Yi-Long, Sequist, Lecia, Tan, Eng-Huat, Geater, Sarayut Lucien, Orlov, Sergey, O'Byrne, Ken, et al. (2018) Afatinib as first-line treatment of older patients with EGFR mutation-positive non-small-cell lung cancer: Subgroup analyses of the LUX-Lung 3, LUX-Lung 6 and LUX-Lung 7 trials. Clinical Lung Cancer, 19(4), e465-e479.

43

12

11

MacDonagh, Lauren, Gray, Steven, Breen, Eamon, Cuffe, Sinead, Finn, Stephen, O'Byrne, Ken, et al. (2018) BBI608 inhibits cancer stemness and reverses cisplatin resistance in NSCLC. Cancer Letters, 428, pp. 117-126.

39

16

13

MacDonagh, L., Gray, S.G., Cuffe, S., Finn, S.P., O?Byrne, K., & Barr, M.P. (2018) BBI608, a small molecule stemness inhibitor, packs a big punch against cisplatin resistant NSCLC. In 16th Annual British Thoracic Oncology Group Conference (BTOG 2018), 2018-01-24 - 2018-01-26.

29

MacDonagh, L., Gray, S.G., Gallagher, M., French, B., Gasch, C., Young, V., et al. (2018) Big applications for a microRNA signature: the diagnostic, prognostic and predictive biomarker potential of a novel 5-miR signature associated with cisplatin resistant NSCLC. In 16th Annual British Thoracic Oncology Group Conference (BTOG 2018), 2018-01-24 - 2018-01-26.

28

MacDonagh, L., Gray, S.G., Gallagher, M., French, B., Gasch, C., Finn, S.P., et al. (2018) A carrot a day keeps recurrence away! The use of vitamin A and its metabolic products in the circumvention of cisplatin resistance via Aldehyde Dehydrogenase 1 (ALDH1). In 16th Annual British Thoracic Oncology Group Conference (BTOG 2018), 2018-01-24 - 2018-01-26.

30

Suraweera, Amila, O'Byrne, Ken, & Richard, Derek (2018) Combination therapy with histone deacetylase inhibitors (HDACi) for the treatment of cancer: Achieving the full therapeutic potential of HDACi. Frontiers in Oncology, 8, Article number: 92 1-15.

41

93

70

Heavey, Susan, Dowling, Paul, Moore, Gillian, Barr, Martin, Kelly, Niamh, Maher, Stephen, et al. (2018) Development and characterisation of a panel of phosphatidylinositide 3-kinase - mammalian target of rapamycin inhibitor resistant lung cancer cell lines. Scientific Reports, 8(1), pp. 1652-1664.

33

3

Wu, Yi-Long, Hirsh, Vera, Sequist, Lecia, Hu, Cheng-Ping, Feng, Jifeng, Lu, Shun, et al. (2018) Does EGFR mutation type influence patient-reported outcomes in patients with advanced EGFR mutation-positive non-small-cell lung cancer? Analysis of two large, phase III studies comparing afatinib with chemotherapy (LUX-Lung 3 and LUX-Lung 6). The Patient, 11(1), pp. 131-141.

23

2

Tickner, Jacob, Richard, Derek, & O'Byrne, Ken (2018) EV, microvesicles/microRNAs and stem cells in cancer. Advances in Experimental Medicine and Biology, 1056, pp. 123-135.

2

MacDonagh, L., Gray, S.G., Cuffe, S., Finn, S.P., Nicholson, S., Ryan, R., et al. (2018) In with the old! Repurposing disulfiram to target cancer stem cells (CSCs) and the root of cisplatin resistance. In 16th Annual British Thoracic Oncology Group Conference (BTOG 2018), 2018-01-24 - 2018-01-26.

24

MacDonagh, L., Gray, S.G., Gallagher, M., French, B., Gasch, C., Finn, S.P., et al. (2018) Is miR-34a the micromanager of cancer stemness and resistance in NSCLC? In 16th Annual British Thoracic Oncology Group Conference (BTOG 2018), 2018-01-24 - 2018-01-26.

27

Hellmann, Matthew D., Ciuleanu, Tudor Eliade, Pluzanski, Adam, Lee, Jong Seok, Otterson, Gregory, Audigier-Valette, Clarisse, et al. (2018) Nivolumab (nivo) + ipilimumab (ipi) vs platinum-doublet chemotherapy (PT-DC) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): initial results from CheckMate 227. In AACR Annual Meeting 2018, 2018-04-14 - 2018-04-18.

17

2

Hellmann, Matthew, Ciuleanu, Tudor-Eliade, Pluzanski, Adam, Lee, Jong Seok, Otterson, Gregory, Audigier-Valette, Clarisse, et al. (2018) Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. The New England Journal of Medicine, 378(22), pp. 2093-2104.

784

618

Soria, Jean-Charles, Ohe, Yuichiro, Vansteenkiste, Johan, Reungwetwattana, Thanyanan, Chewaskulyong, Busyamas, O'Byrne, Ken, et al. (2018) Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. The New England Journal of Medicine, 378(2), pp. 113-125.

851

636

Yang, J.C.-., Wu, Y., Hirsh, V., O?Byrne, K., Yamamoto, N., Popat, S., et al. (2018) P06 competing CNS or systemic progression analysis for EGFR mutation-positive NSCLC patients on afatinib in LUX-Lung 3, 6, and 7. In IASLC Latin America Conference on Lung Cancer 2018, 2018-08-15 - 2018-08-18.

25

Metaxas, Yannis, Rivalland, Gareth, Mauti, Laetitia, Klingbiel, Dirk, Kao, Steven, O'Byrne, Ken, et al. (2018) Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma. Journal of Thoracic Oncology, 13(11), pp. 1784-1791.

19

13

Kapeleris, Joanna, Kulasinghe, Arutha, Ebrahimi Warkiani, Majid, Vela, Ian, Kenny, Lizbeth, O'Byrne, Ken, et al. (2018) The prognostic role of circulating tumor cells (CTCs) in lung cancer. Frontiers in Oncology, 8, Article number: 311 1-13.

51

21

14

Kulasinghe, Arutha, Kapeleris, Joanna, Kimberley, Rebecca, Mattarollo, Stephen, Thompson, Rik, Thiery, Jean-Paul, et al. (2018) The prognostic significance of circulating tumor cells in head and neck and non-small-cell lung cancer. Cancer Medicine, 7(12), pp. 5910-5919.

45

18

11

Duffy, Michael & O'Byrne, Ken (2018) Tissue and blood biomarkers in lung cancer: A review. Advances in Clinical Chemistry, 86, pp. 1-21.

6

2

Ramalingam, Suresh, Hellmann, Matthew, Awad, Mark, Borghaei, Hossein, Gainor, Justin, Brahmer, Julie, et al. (2018) Tumor mutational burden (TMB) as a biomarker for clinical benefit from dual immune checkpoint blockade with nivolumab (nivo) + ipilimumab (ipi) in first-line (1L) non-small cell lung cancer (NSCLC): identification of TMB cutoff from CheckMate 568. Cancer Research, 78(13S), CT078-CT078.

30

21

Rivalland, Gareth, Kao, Chuan-Hao, Pavlakis, Nick, Hughes, Brett Gordon Maxwell, Bibhusal, Thapa, Pal, Abhijit, et al. (2017) Outcomes of anti-PD-1 therapy in mesothelioma and correlation with PD-L1 expression. In ASCO 2017, 2017-06-02 - 2017-06-06.

37

Barr, M.P., Singh, S., Foley, E., He, Y., Young, V., Ryan, R., et al. (2017) 2: XRCC6BP1: A key player in cisplatin resistance and lung cancer stem cells. In 15th Annual Bristish Thoracic Oncology Group Conference, 2017-01-25 - 2017-01-27.

Baird, A., Easty, D., Mohamed, B.M., Jarzabek, M., Shiels, L., Soltermann, A., et al. (2017) Multiple RTK targeting as a therapeutic option in malignant pleural mesothelioma. In 15th Annual British Thoracic Oncology Group Conference, 2017-01-25 - 2017-01-27.

Burgess, Joshua T., Bolderson, Emma, Gray, Steven, Barr, Martin, Gately, Kathy, Zhang, Shu-Dong, et al. (2017) The Overexpression and Cleavage of SASH1 by Caspase-3 Stimulates Cell Death in Lung Cancer Cells. In Abstracts from the IASLC 17th World Conference on Lung Cancer, 2016-12-04 - 2016-12-07.

Ryan, Sarah-Louise, Godwin, Peter, Heavey, Susan, Umezawa, Kazuo, Barr, Martin, Gray, Steven, et al. (2017) P2.01-031 CCL Chemokines May Play an Important Role in Cisplatin Resistance. In The IASLC 17th World Conference on lung cancer, 2016-12-04 - 2016-12-07.

Barr, Martin, Singh, Saravjeet, Foley, Emma, He, Yuexi, Young, Vincent, Ryan, Ronan, et al. (2017) P2.03a-062 Characterization and Targeting of the DNA Repair Gene, XRCC6BP1, in Cisplatin Resistant NSCLC. In The IASLC 17 World Conference on Lung Cancer, 2016-12-04 - 2016-12-07.

Donagh, Lauren Mac, Gray, Steven, Finn, Stephen, Cuffe, Sinead, Gallagher, Michael, O?Byrne, Kenneth, et al. (2017) P2.03a-064 Inhibition and Exploitation of Aldehyde Dehydrogenase 1 as a Cancer Stem Cell Marker to Overcome Cisplatin Resistant NSCLC. In The IASLC 17th World Conference on lung cancer, 2016-12-04 - 2016-12-07.

Ryan, Sarah-Louise, Baird, Anne-Marie, Lu, Z., Urquhart, Aaron, Barr, Martin, Richard, Derek, et al. (2017) P2.03b-096 Utilization of a Novel 3D Culture Technology for the Assessment of Chemo-Resistance in Non-Small Cell Lung Cancer. In IASLC 17th World Conference on Lung Cancer, 2016-12-04 - 2016-12-07.

Baird, Anne-Marie, Barr, Martin, Ryan, Sarah-Louise, Gray, Steven, Davies, Anthony, Cuffe, Sinead, et al. (2017) P3.01-042 Lung Cancer Cells Can Stimulate Functional and Genotypic Modifications in Normal Bronchial Epithelial Cells. In IASLC 17th World Conference on Lung Cancer, 2016-12-04 - 2016-12-07.

38

Paz-Ares, Luis, Tan, Eng-Huat, O'Byrne, Ken, Zhang, L., Hirsh, Vera, & other, and (2017) Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial. Annals of Oncology, 28(2), pp. 270-277.

95

167

141

Ferry, David, Billingham, Lucinda, Jarrett, Hugh, Dunlop, David, Woll, Penella, Nicolson, Marianne, et al. (2017) Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer: Results from a British Thoracic Oncology Group randomised phase III trial. European Journal of Cancer, 83, pp. 302-312.

58

7

6

Ryan, Sarah-Louise, Godwin, Peter, Heavey, Susan, Umezawa, Kazuo, Barr, Martin, Gray, Steven, et al. (2017) CCL chemokines may play an important role in cisplatin resistance: Topic: proteins in lung cancer and proteomics (Conference Abstract). Journal of Thoracic Oncology, 12(1(S)), S803-S804.

25

Adams, Mark, Burgess, Joshua, Gately, Kathy, Snell, Cameron, Richard, Derek, & O'Byrne, Ken (2017) CDCA3 is a novel prognostic cell cycle protein and target for therapy in non-small cell lung cancer: Topic: Marker for prognosis (Conference Abstract). Journal of Thoracic Oncology, 12(1(S)), S837-S837.

27

Antonia, Scott, Villegas, Augusto, Daniel, Davey, Vicente, David, Murakami, Shuji, Hui, Rina, et al. (2017) Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. The New England Journal of Medicine, 377, pp. 1919-1929.

366

961

898

Wu, Yi-Long, Sequist, Lecia, Hu, Cheng-Ping, Feng, Jifeng, Lu, Shun, Huang, Yunchao, et al. (2017) EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6. British Journal of Cancer, 116(2), pp. 175-185.

46

42

28

Kulasinghe, Arutha Jeevana, Tran, Thao Huynh Phuoc, Blick, Tony, O'Byrne, Ken, Thompson, Rik, Ebrahimi Warkiani, Majid, et al. (2017) Enrichment of circulating head and neck tumour cells using spiral microfluidic technology. Scientific Reports, 7, Article number: 42517 1-10.

71

28

24

Adams, Mark, Burgess, Joshua, He, Yaowu, Gately, Kathy, Snell, Cameron, Zhang, Shu-Dong, et al. (2017) Expression of CDCA3 is a prognostic biomarker and potential therapeutic target in non-small cell lung cancer. Journal of Thoracic Oncology, 12(7), pp. 1071-1084.

10

6

Carbone, David, Reck, Martin, Paz-Ares, Luis, Creelan, Benjamin, Horn, Leora, Steins, Martin, et al. (2017) First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. The New England Journal of Medicine, 376(25), pp. 2415-2426.

131

778

646

Croft, Laura, Ashton, Nicholas, Paquet, Nicolas, Bolderson, Emma, O'Byrne, Ken, & Richard, Derek (2017) hSSB1 associates with and promotes stability of the BLM helicase. BMC Molecular Biology, 18, Article number: 13 1-10.

3

2

Ashton, Nicholas, Paquet, Nicolas, Shirran, Sally, Bolderson, Emma, Kariawasam, Ruvini, Touma, Christine, et al. (2017) hSSB1 phosphorylation is dynamically regulated by DNA-PK and PPP-family protein phosphatases. DNA Repair, 54, pp. 30-39.

97

4

Roberts, Kate, Culleton, Vanessa, Lwin, Zarnie, O'Byrne, Ken, & Hughes, Brett (2017) Immune checkpoint inhibitors: Navigating a new paradigm of treatment toxicities. Asia-Pacific Journal of Clinical Oncology, 13(4), pp. 277-288.

31

16

14

Cregan, Sian, Breslin, Maeve, Roche, Gerard, Wennstedt, Sigrid, MacDonagh, Lauren, Albadri, Cinaria, et al. (2017) Kdm6a and Kdm6b: Altered expression in malignant pleural mesothelioma. International Journal of Oncology, 50(3), pp. 1044-1052.

5

Baird, Anne-Marie, Barr, Martin, Ryan, Sarah-Louise, Gray, Steven, Davies, Anthony, Cuffe, Sinead, et al. (2017) Lung cancer cells can stimulate functional and genotypic modifications in normal bronchial epithelial cells: Topic: Functional biology in lung cancer (Conference Abstract). Journal of Thoracic Oncology, 12(1(S)), S1145-S1145.

Circu, Magdalena, Cardelli, James, Barr, Martin, O'Byrne, Ken, Mills, Glenn, & El-Osta, Hazem (2017) Modulating lysosomal function through lysosome membrane permeabilization or autophagy suppression restores sensitivity to cisplatin in refractory non-small-cell lung cancer cells. PLoS One, 12(9), Article number: e0184922 1-23.

31

9

8

Baird, Anne-Marie, Barr, Martin, Ryan, Sarah-Louise, Gray, Steven, Davies, Anthony, Cuffe, Sinead, et al. (2017) Normal bronchial epithelial cells exhibit altered cellular behaviour when exposed to lung cancer cells in a co-culture system (Conference Abstract). Lung Cancer, 103(S1), S4-S4.

Jaffary, Syed Ali Naqi Raza, Adams, Mark, Fisher, Mark, Beard, Sam, Burgess, Joshua, O'Byrne, Ken, et al. (2017) Novel role of hSSB2 in the Base Excision Repair Pathway (BER) (Conference Abstract). Journal of Thoracic Oncology, 12(11), Article number: S2 S1928-S1928.

O'Byrne, Ken & Richard, Derek (2017) Nucleolar caspase-2: Protecting us from DNA damage. Journal of Cell Biology, 216(6), pp. 1521-1523.

30

2

Mok, Tony, Wu, Yi-Long, Ahn, Myung-Ju, Garassino, Marina, Kim, Hye, O'Byrne, Ken, et al. (2017) Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. The New England Journal of Medicine, 376(7), pp. 629-640.

479

1,050

896

Feng, Sophie, Coward, Jim, McCaffrey, Elizabeth, Coucher, John, Kalokerinos, Paul, & O'Byrne, Ken (2017) Pembrolizumab induced encephalopathy: a review of neurological toxicities with immune checkpoint inhibitors. Journal of Thoracic Oncology, 12(11), pp. 1626-1635.

25

17

Govindan, Ramaswamy, Szczesna, Aleksandra, Jassem, Jacek, Ahn, Myung-Ju, Lee, Ki Hyeong, Schneider, Claus-Peter, et al. (2017) Phase III trial of ipilimumab combined with paclitaxel and carboplatin in advanced squamous non-small-cell lung cancer. Journal of Clinical Oncology, 35(30), pp. 3449-3459.

55

117

87

Ladwa, Rahul, Gustafson, Sonja, McCaffrey, Elizabeth, Miles, Kenneth, & O'Byrne, Ken (2017) A rare case of omentum invasive prostate cancer: Staging with PSMA PET/CT imaging and response to systemic therapy. Clinical Nuclear Medicine, 42(6), e311-e312.

4

2

Spigel, David, Edelman, Martin, O'Byrne, Ken, Paz-Ares, Luis, Mocci, Simonetta, Phan, See, et al. (2017) Results from the phase III randomized trial of onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIB or IV non-small-cell lung cancer: METLung. Journal of Clinical Oncology, 35(4), pp. 412-420.

102

95

92

Adams, Mark, Burgess, Joshua, Richard, Derek, & O'Byrne, Ken (2017) Targeting CDCA3 enhances sensitivity to platinum-based chemotherapy in non-small cell lung cancer (Conference Abstract). Journal of Thoracic Oncology, 12(11), Article number: S2 S1810-S1811.

MacDonagh, Lauren, Gallagher, Michael, Ffrench, Brendan, Gasch, Claudia, Breen, Eamon, Gray, Steven, et al. (2017) Targeting the cancer stem cell marker, aldehyde dehydrogenase 1, to circumvent cisplatin resistance in NSCLC. OncoTarget, 8(42), pp. 72544-72563.

29

20

O'Byrne, Kenneth (2017) Transforming KRAS into a clinically relevant biomarker (Conference Abstract). Journal of Thoracic Oncology, 12(1(S)), S139-S140.

Collins, Denis, Gately, Kathy, Hughes, Clare, Edwards, Connla, Davies, Anthony, Madden, Stephen, et al. (2017) Tyrosine kinase inhibitors as modulators of trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity in breast cancer cell lines. Cellular Immunology, 319, pp. 35-42.

10

9

Ryan, Sarah-Louise, Baird, Anne-Marie, Lu, Z., Urquhart, Aaron, Barr, Martin, Richard, Derek, et al. (2017) Utilization of a novel 3D culture technology for the assessment of chemo-resistance in non-small cell lung cancer: Topic: biomarkers (Conference Abstract). Journal of Thoracic Oncology, 12(1(S)), S994-S995.

Baird, Anne-Marie, Easty, David, Jarzabek, Monika, Shiels, Liam, Soltermann, Alex, O'Byrne, Ken, et al. (2017) When RON MET TAM in mesothelioma: All druggable for one, and one drug for all?: Topic: Mesothelioma transitional (Conference Abstract). Journal of Thoracic Oncology, 12(1(S)), S1356-S1357.

23

Fein, Luis, Wu, Yi-Long, Sequist, Lecia V., Geater, Sarayut L., Orlov, Sergey, Lee, Ki Hyeong, et al. (2016) P1.33: Afatinib versus chemotherapy for EGFR mutation-positive NSCLC patients aged ≥65 years: Subgroup Analysis of LUX-Lung 3/6: Track: Advanced NSCLC. In IASLC 7th Latin American Conference on Lung Cancer (LALCA), 2016-08-25 - 2016-08-27.

Aix, Santiago Ponce, Park, Keunchil, Tan, Eng-Huat, O?Byrne, Kenneth, Zhang, Li, Boyer, Michael, et al. (2016) P1.34: First-Line Afatinib vs Gefitinib for Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: The LUX-Lung 7 Trial. In IASLC 7th Latin American Conference on Lung Cancer, 2016-08-25 - 2016-08-27.

Barrios, Carlos H., Wu, Yi-Long, Chih-Hsin Yang, James, Sequist, Lecia V., Geater, Sarayut L., Mok, Tony, et al. (2016) P1.45: Impact of Dose Adjustment on Afatinib Safety and Efficacy in EGFR Mutation-Positive NSCLC: Post-Hoc Analyses of LUX-Lung 3/6. In IASLC 7th Latin American Conference on Lung Cancer, 2016-08-25 - 2016-08-27.

Mitchell, Paul, Siva, Shankar, Kok, Peey Sei, O'Byrne, Kenneth, Yeung, Annie, Livingstone, Ann, et al. (2016) NIVORAD: A randomised phase 2 trial of nivolumab and stereotactic ablative body radiotherapy in advanced non-small cell lung cancer, progressing after first or second line chemotherapy. In ASCO 2017, 2017-06-02 - 2017-06-06.

51

Schuler, M., Yang, J., Sequist, L.V., Yamamoto, N., Zhou, C., O'Byrne, K., et al. (2016) 138PD: Impact of dose adjustment on the safety and efficacy of afatinib in patients (pts) with advanced EGFR mutation-positive non-small cell lung cancer (NSCLC): Post-hoc analyses of LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6). In European Lung Cancer Conference (ELCC 2016), 2016-04-13 - 2016-04-16.

2

1

Barr, M.P., MacDonagh, L., Gray, S.G., O'Byrne, K., Cuffe, S., & Finn, S. (2016) 75P inhibition and exploitation of aldehyde dehydrogenase 1 (ALDH1) as a cancer stem cell marker in cisplatin resistant NSCLC. In ELCC 2016 European Lung Cancer Conference, 2016-04-13 - 2016-04-16.

37

2

Barr, M.P., Foley, E., He, Y., Young, V., Ryan, R., Nicholson, S., et al. (2016) 80P XRCC6BP1: A key DNA repair gene in platinum-resistant NSCLC. In European Lung Cancer Conference (ELCC 2016), 2016-04-13 - 2016-04-16.

Barr, M.P., MacDonagh, L., Gray, S.G., Reidy, M., Sui, J. Sze Yin, Nicholson, S., et al. (2016) 70P Identification of a novel microRNA signature: Potential diagnostic biomarkers and predictors of cisplatin response? In The IASLC 17th World Conference on lung cancer, 2016-12-04 - 2016-12-07.

Burgess, Joshua, Bolderson, Emma, Adams, Mark, Baird, Anne-Marie, Zhang, Shu-Dong, Gately, Kathy, et al. (2016) Activation and cleavage of SASH1 by caspase-3 mediates an apoptotic response. Cell Death and Disease, 7, Article number: e2469 1-8.

43

6

Paz-Ares, Luis, Tan, Eng-Huat, Zhang, L., Hirsh, Vera, O'Byrne, Ken, & other, and (2016) Afatinib (A) vs gefitinib (G) in patients (pts) with EGFR mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC): overall survival (OS) data from the phase IIb trial LUX-Lung 7 (LL7) (Conference Abstract). Annals of Oncology, 27(S6), LBA43-LBA43.

141

Park, Keunchil, Tan, Eng-Huat, O'Byrne, Ken, Zhang, Li, Boyer, Michael, Mok, Tony, et al. (2016) Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. The Lancet Oncology, 17(5), pp. 577-589.

424

383

Cathcart, Mary-Clare, Useckaite, Zivile, Drakeford, Clive, Semik, Vikki, Lysaght, Joanne, Gately, Kathy, et al. (2016) Anti-cancer effects of baicalein in non-small cell lung cancer in-vitro and in-vivo. BMC Cancer, 16, Article number: 707 1-13.

63

21

23

O'Byrne, Ken, Adams, Mark, Burgess, Joshua, & Richard, Derek (2016) CDCA3 regulates the cell cycle and modulates cisplatin sensitivity in non-small cell lung cancer [Conference Abstract - ELCC 2016]. Journal of Thoracic Oncology, 11(4), S65-S65.

4

DeCatris, Marios, Farrugia, David, & O'Byrne, Ken (2016) Clinician perspective on molecular profiling of non-small-cell lung cancer [Correspondence]. Journal of Clinical Oncology, 34(8), pp. 884-886.

5

Ramalingam, Suresh, O'Byrne, Ken, Boyer, Michael, Mok, Tony, Janne, Pasi, Zhang, H., et al. (2016) Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials. Annals of Oncology, 27(3), pp. 423-429.

71

40

35

Ryan, Sarah-Louise, Baird, Anne-Marie, Vaz, Gisela, Urquhart, Aaron, Senge, Mathias, Richard, Derek, et al. (2016) Drug discovery approaches utilizing three-dimensional cell culture. Assay and Drug Development Technologies, 14(1), pp. 19-28.

33

23

Yang, James Chih-Hsin, Sequist, Lecia, Zhou, Caicun, Schuler, Martin, Geater, Sarayut Lucien, Mok, Tony, et al. (2016) Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials. Annals of Oncology, 27(11), pp. 2103-2110.

74

67

O'Byrne, Ken, Ryan, Sarah-Louise, Baird, Anne-Marie, Urquhart, Aaron, Richard, Derek, & Davies, Anthony (2016) Elucidating drug resistance mechanisms using 2D and 3D culture systems [Conference Abstract - ELCC 2016]. Journal of Thoracic Oncology, 11(4), S86-S87.

1

Kulasinghe, Arutha Jeevana, Perry, Chris, Boyle, Glen, O'Byrne, Ken, Davies, Anthony, Jovanovic, Lidija, et al. (2016) Epithelial-mesenchymal axis in head and neck cancer cell lines. Journal of Solid Tumors, 6(1), pp. 28-37.

219

O'Byrne, Ken, Paquet, Nicolas, Box, Joseph, Adams, Mark, & Richard, Derek (2016) Examination of EXOSC4 as a new prognostic marker and a novel therapeutic avenue in lung adenocarcinoma [Conference Abstract- ELCC 2016]. Journal of Thoracic Oncology, 11(4), S63-S63.

3

Schuler, Martin, Wu, Yi-Long, Hirsh, Vera, O'Byrne, Ken, Yamamoto, Nobuyuki, Mok, Tony, et al. (2016) First-line afatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases. Journal of Thoracic Oncology, 11(3), pp. 380-390.

162

141

127

Sharkey, Annabel, O'Byrne, Ken, Nakas, Apostolos, Tenconi, Sara, Fennell, Dean, & Waller, David (2016) How does the timing of chemotherapy affect outcome following radical surgery for malignant pleural mesothelioma? Lung Cancer, 100, pp. 5-13.

11

10

Paquet, Nicolas, Adams, Mark, Ashton, Nicholas, Touma, Christine, Gamsjaeger, Roland, Cubeddu, Liza, et al. (2016) hSSB1 (NABP2/OBFC2B) is regulated by oxidative stress. Scientific Reports, 6, Article number: 27446 1-13.

10

DeCatris, Marios & O'Byrne, Ken (2016) Immune checkpoint inhibitors as first-line and salvage therapy for advanced non-small-cell lung cancer. Future Oncology, 12(15), pp. 1805-1822.

5

3

Heavey, Susan, Cuffe, Sinead, Finn, Stephen, Young, Vincent, Ryan, Ronan, Nicholson, Siobhan, et al. (2016) In pursuit of synergy: An investigation of the PI3K/mTOR/MEK co-targeted inhibition strategy in NSCLC. OncoTarget, 7(48), pp. 79526-79543.

49

12

O'Byrne, Ken, Ryan, Sarah-Louise, Heavey, Susan, Umezawa, Kazuo, Barr, M, Gray, Steven, et al. (2016) Inflammatory meditated mechanisms of cisplatin resistance in non-small cell lung cancer [Conference Abstract- ELCC 2016]. Journal of Thoracic Oncology, 11(4), S84-S84.

O'Byrne, Ken, Barr, M, Urquhart, Aaron, Ryan, Sarah-Louise, Gray, Steven, Davies, Anthony, et al. (2016) Investigation of the interaction between non-small cell lung cancer cells and immortalised normal bronchial epithelial cells [Conference Abstract- ELCC 2016]. Journal of Thoracic Oncology, 11(4), S83-S84.

Cregan, Sian, McDonagh, Laura, Gao, Yun, Barr, Martin, O'Byrne, Ken, Finn, Stephen, et al. (2016) KAT5 (Tip60) is a potential therapeutic target in malignant pleural mesothelioma. International Journal of Oncology, 48(3), pp. 1290-1296.

49

12

10

MacDonagh, Lauren, Gray, Steven, Breen, Eamon, Cuffe, Sinead, Finn, Stephen, O'Byrne, Ken, et al. (2016) Lung cancer stem cells: The root of resistance. Cancer Letters, 372(2), pp. 147-156.

52

46

Ashton, Nicholas, Loo, Dorothy, Paquet, Nicolas, O'Byrne, Ken, & Richard, Derek (2016) Novel insight into the composition of human single-stranded DNA-binding protein 1 (hSSB1)-containing protein complexes. BMC Molecular Biology, 17, Article number: 24 1-8.

45

5

4

Box, Joseph, Paquet, Nicolas, Adams, Mark, Boucher, Didier, Bolderson, Emma, O'Byrne, Ken, et al. (2016) Nucleophosmin: from structure and function to disease development. BMC Molecular Biology, 17, Article number: 19 1-12.

51

70

58

O'Byrne, Ken, Burgess, Joshua, Bolderson, Emma, Adams, Mark, Zhang, S, & Richard, Derek (2016) The overexpression of SASH1 stimulates cell death in lung cancer cells [Conference Abstract- ELCC 2016]. Journal of Thoracic Oncology, 11(4), S62-S63.

1

Reck, Martin, Rodriguez-Abreu, Delvys, Robinson, Andrew, Hui, Rina, Csoszi, Tibor, O'Byrne, Ken, et al. (2016) Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. The New England Journal of Medicine, 375(19), pp. 1823-1833.

2,948

2,563

Baird, Anne-Marie, Gray, Steven, Richard, Derek, & O'Byrne, Ken (2016) Promotion of a cancer-like phenotype, through chronic exposure to inflammatory cytokines and hypoxia in a bronchial epithelial cell line model. Scientific Reports, 6, Article number: 18907 1-14.

43

4

Burgess, Joshua, Bolderson, Emma, Saunus, Jodi, Zhang, Shu-Dong, Reid, Lynne, McNicol, Anne Marie, et al. (2016) SASH1 mediates sensitivity of breast cancer cells to chloropyramine and is associated with prognosis in breast cancer. OncoTarget, 7(45), pp. 72807-72818.

73

9

8

Kulasinghe, Arutha Jeevana, Perry, Chris, Ebrahimi Warkiani, Majid, Blick, Tony, Davies, Anthony, O'Byrne, Ken, et al. (2016) Short term ex-vivo expansion of circulating head and neck tumour cells. OncoTarget, 7(37), pp. 60101-60109.

83

20

18

Touma, Christine, Kariawasam, Ruvini, Gimenez, Adrian, Bernardo, Ray, Ashton, Nicholas, Adams, Mark, et al. (2016) A structural analysis of DNA binding by hSSB1 (NABP2/OBFC2B) in solution. Nucleic Acids Research, 44(16), pp. 7963-7973.

64

10

9

Hallinan, Niamh, Finn, Stephen, Cuffe, Sinead, Rafee, Shereen, O'Byrne, Ken, & Gately, Kathy (2016) Targeting the fibroblast growth factor receptor family in cancer. Cancer Treatment Reviews, 46, pp. 51-62.

136

40

39

Elamin, Yasir, Rafee, Shereen, Osman, Nemer, O'Byrne, Ken, & Gately, Kathy (2016) Thymidine phosphorylase in cancer; enemy or friend? Cancer Microenvironment, 9(1), pp. 33-43.

46

32

28

Eberhardt, Wilfried, De Ruysscher, Dave, Weder, Walter, Le Pechoux, Cecile, De Leyn, Paul, Hoffmann, Hans, et al. (2015) 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer. Annals of Oncology, 26(8), pp. 1573-1588.

166

137

Dowling, Paul, Pollard, Damian, Larkin, Anne Marie, Henry, Michael, Meleady, Paula, Gately, Kathy, et al. (2015) Abnormal levels of heterogeneous nuclear ribonucleoprotein A2B1 (hnRNPA2B1) in tumour tissue and blood samples from patients diagnosed with lung cancer. Molecular BioSystems, 11(3), pp. 743-752.

11

Yang, James Chih-Hsin, Wu, Yi-Long, Schuler, Martin, Sebastian, Martin, Popat, Sanjaykumarv, Yamamoto, Nobuyuki, et al. (2015) Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. The Lancet Oncology, 16(2), pp. 141-151.

999

831

763

Vansteenkiste, Johan, Barlesi, Fabrice, Waller, C., Bennouna, Jaafar, Gridelli, Cesare, Goekkurt, Eray, et al. (2015) Cilengitide combined with cetuximab and platinum-based chemotherapy as first-line treatment in advanced non-small-cell lung cancer (NSCLC) patients: results of an open-label, randomized, controlled phase II study (CERTO). Annals of Oncology, 26(8), pp. 1734-1740.

38

29

MacDonagh, Lauren, Gray, Steven, Finn, Stephen, Cuffe, Sinead, & O'Byrne, Ken (2015) The emerging role of microRNAs in resistance to lung cancer treatments. Cancer Treatment Reviews, 41(2), pp. 160-169.

70

66

Baird, Anne-Marie, Richard, Derek, O'Byrne, Ken, & Gray, Steven (2015) Epigenetic therapy in lung cancer and mesothelioma. In Gray, S (Ed.) Epigenetic cancer therapy. Academic Press, United Kingdom, pp. 189-213.

3

Richard, Derek, Bolderson, Emma, Baird, Anne-Marie, & O'Byrne, Ken (2015) Epigenetics underpinning DNA damage repair. In Gray, S (Ed.) Epigenetic cancer therapy. Academic Press, United Kingdom, pp. 595-612.

1

Paquet, Nicolas, Adams, Mark, Leong, Vincent, Ashton, Nicholas, Touma, Christine, Gamsjaeger, Roland, et al. (2015) hSSB1 (NABP2/ OBFC2B) is required for the repair of 8-oxo-guanine by the hOGG1-mediated base excision repair pathway. Nucleic Acids Research, 43(18), pp. 8817-8829.

54

24

23

Baird, Anne-Marie, Barr, Martin, Urquhart, Aaron, Ryan, Sarah-Louise, Gray, Steven, Davies, Anthony, et al. (2015) Lung cancer cells can alter the behaviour of normal bronchial epithelial cells through multiple mechanisms. In IASLC World Conference on Lung Cancer, 2015-09-06 - 2015-09-09.

Dowling, Paul, Henry, Michael, Meleady, Paula, Clarke, Colin, Gately, Kathy, O'Byrne, Ken, et al. (2015) Metabolomic and proteomic analysis of breast cancer patient samples suggests that glutamate and 12-HETE in combination with CA15-3 may be useful biomarkers reflecting tumour burden. Metabolomics, 11(3), pp. 620-635.

7

6

Gately, Kathy, Forde, Lydia, Gray, Steven, Morris, Derek, Corvin, Aiden, Tewari, Prerna, et al. (2015) Mutational analysis of the insulin-like growth factor 1 receptor tyrosine kinase domain in non-small cell lung cancer patients. Molecular and Clinical Oncology, 3(5), pp. 1073-1079.

65

2

Rafee, Shereen, Elamin, Yasir, Joyce, Eimear, Toner, Mary, Flavin, Richard, McDermott, Ronan, et al. (2015) Neoadjuvant crizotinib in advanced inflammatory myofibroblastic tumour with ALK gene rearrangement. Tumori, 101(2), e35-e39.

7

6

Mongan, Ann Marie, Kalachand, Roshni, King, Sinead, O'Farrell, N., Power, D., Ravi, N., et al. (2015) Outcomes in gastric and junctional cancer using neoadjuvant and adjuvant chemotherapy (epirubicin, oxaliplatin, and capecitabine) and radical surgery. Irish Journal of Medical Science, 184(2), pp. 417-423.

7

5

O'Byrne, Ken (2015) Stimulating immune responses to fight cancer: Basic biology and mechanisms. Asia-Pacific Journal of Clinical Oncology, 11(S1), pp. 9-15.

4

Baird, Anne-Marie, Godwin, Peter, Heavey, Susan, Umezawa, Kazuo, Barr, Martin, Davies, Anthony, et al. (2015) Targeting inflammatory mediators to overcome intrinsic and acquired cisplatin resistance in non-small cell lung cancer. In IASLC World Conference on Lung Cancer, 2015-09-06 - 2015-09-09.

5

O'Callaghan, Dermot, Rexhepaj, Elton, Gately, Kathy, Coate, Linda, Delaney, David, O'Donnell, Dearbhaile, et al. (2015) Tumour islet Foxp3+ T-cell infiltration predicts poor outcome in nonsmall cell lung cancer. European Respiratory Journal, 46(6), pp. 1762-1772.

36

25

16

Barr, Martin, Gray, Steven, Gately, Kathy, Hams, Emily, Fallon, Padraic, Davies, Anthony, et al. (2015) Vascular endothelial growth factor is an autocrine growth factor, signaling through neuropilin-1 in non-small cell lung cancer. Molecular Cancer, 14, Article number: 45 1-15.

37

33

31

Barr, Martin, O'Byrne, Ken, Al-Sarraf, Nael, & Gray, Steven (2015) VEGF-mediated cell survival in non-small-cell lung cancer: implications for epigenetic targeting of VEGF receptors as a therapeutic approach. Epigenomics, 7(6), pp. 897-910.

4

2

Barr, M.P., Buckley, P.G., Alcock, L.C., Stallings, R.L., Toomey, S., Carr, A., et al. (2014) Chromosomal and mutational analysis of the cisplatin resistant phenotype in NSCLC. In 12th Annual British Thoracic Oncology Group Conference, 2014-01-29 - 2014-01-31.

Barr, M.P., Rausch, R., Thomale, J., Richard, D., Cuffe, S., Finn, S., et al. (2014) Inhibition of PARP activity by PJ34 sensitises NSCLC cells to cisplatin. In 12th Annual British Thoracic Oncology Group Conference, 2014-01-29 - 2014-01-31.

Baird, A.-M., Godwin, P., Heavey, S., Umezawa, K., Barr, M.P., Richard, D., et al. (2014) Targeting NF-κB regulated pathways to overcome cisplatin resistance in non-small cell lung cancer. In 12th Annual British Thoracic Oncology Group Conference, 2014-01-29 - 2014-01-31.

Barr, M.P., Gray, G., Gately, K.A., Hams, E., Fallon, P.G., Davies, A. Mitchell, et al. (2014) VEGF autocrine survival signalling is mediated via neuropilin 1 receptor in NSCLC cells. In 12th Annual British Thoracic Oncology Group Conference, 2014-01-29 - 2014-01-31.

1

Vansteenkiste, Johan, Crino, Lucio, Dooms, Christophe, Douillard, Jean-Yves, Faivre-Finn, Corinne, Lim, E., et al. (2014) 2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. Annals of Oncology, 25(8), pp. 1462-1474.

200

204

Besse, Benjamin, Adjei, A., Baas, Paul, Meldgaard, P., Nicolson, Marianne, Paz-Ares, Luis, et al. (2014) 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. Annals of Oncology, 25(8), pp. 1475-1484.

143

132

Jekimovs, Christian, Bolderson, Emma, Suraweera, Amila, Adams, Mark, O'Byrne, Ken, & Richard, Derek (2014) Chemotherapeutic compounds targeting the DNA double-strand break repair pathways: the good, the bad, and the promising. Frontiers in Oncology, 4, Article number: 86 1-18.

126

62

36

Burgess, Joshua, Croft, Laura, Wallace, Nathan, Stephenson, Sally-Anne, Adams, Mark, Ashton, Nicholas, et al. (2014) DNA repair pathways and their therapeutic potential in lung cancer. Lung Cancer Management, 3(2), pp. 159-173.

79

Barr, Martin, Lina, Souan, MacGabhann, Peadar, Muller, Jeanette, Al Ashhab, Maxim, Jasser, Mohammed, et al. (2014) The establishment of an ISO compliant cancer biobank for Jordan and its neighboring countries through knowledge transfer and training. Biopreservation and Biobanking, 12(1), pp. 3-12.

8

7

Tickner, Jacob, Urquhart, Aaron, Stephenson, Sally-Anne, Richard, Derek, & O'Byrne, Ken (2014) Functions and therapeutic roles of exosomes in cancer. Frontiers in Oncology, 4, Article number: 127 1-8.

42

129

57

Elamin, Yasir, Rafee, Shereen, Nur, Mutaz, Osman, Nemer, Reynolds, John, Muldoon, Cian, et al. (2014) HER2 positive gastric and gastroesophageal adenocarcinoma; An Irish tertiary center experience. International Journal of Cancer and Clinical Research, 1(2), pp. 1-4.

31

Gately, Kathy, Forde, Lydia, Cuffe, Sinead, Cummins, Robert, Kay, Elaine, Feuerhake, Friedrich, et al. (2014) High coexpression of both EGFR and IGF1R correlates with poor patient prognosis in resected non-small-cell lung cancer. Clinical Lung Cancer, 15(1), pp. 58-66.

32

31

Adams, Mark, Ashton, Nicholas, Paquet, Nicolas, O'Byrne, Ken, & Richard, Derek (2014) Mechanisms of cisplatin resistance: DNA repair and cellular implications. In Morais, C (Ed.) Advances in drug resistance research. Nova Science Publishers, United States of America, pp. 1-38.

Pujol, Jean-Louis, Pirker, Robert, Lynch, Thomas, Butts, Charles, Rosell, Rafael, Shepherd, Frances, et al. (2014) Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer. Lung Cancer, 83(2), pp. 211-218.

55

50

d'Adhemar, Charles, Spillane, Cathy, Gallagher, Michael, Bates, Mark, Costello, Katie, Barry-O'Crowley, Jacqui, et al. (2014) The MyD88+ phenotype is an adverse prognostic factor in epithelial ovarian cancer. PLoS One, 9(6), Article number: e108833 1-15.

47

26

25

Cooper, Wendy, Fox, Stephen, O'Toole, Sandra, Morey, Adrienne, Frances, Glenn, Pavlakis, Nick, et al. (2014) National Working Group Meeting on ALK diagnostics in lung cancer. Asia-Pacific Journal of Clinical Oncology, 10(S2), pp. 11-17.

14

13

Paquet, Nicolas, Box, Joseph, Ashton, Nicholas, Suraweera, Amila, Croft, Laura, Urquhart, Aaron, et al. (2014) Nestor-Guillermo Progeria Syndrome: a biochemical insight into Barrier-to-Autointegration Factor 1, alanine 12 threonine mutation. BMC Molecular Biology, 15, Article number: 27 1-11.

46

13

15

O'Brien, Cathal, Langabeer, Stephen, O'Byrne, Kenneth, O'Leary, John, & Finn, Stephen (2014) Predictive values for molecular diagnostics: converting unknown unknowns to known unknowns. Molecular Diagnosis and Therapy, 18(1), pp. 1-4.

1

2

Blackhall, Fiona, Peters, Solange, Bubendorf, Lukas, Dafni, Urania, Kerr, Keith, Hager, Henrik, et al. (2014) Prevalence and clinical outcomes for patients with ALK-positive resected Stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project. Journal of Clinical Oncology, 32(25), pp. 2780-2787.

115

103

Al-Alao, Bassel, Gately, Kathy, Nicholson, Siobhan, McGovern, Eilis, Young, Vincent, & O'Byrne, Ken (2014) Prognostic impact of vascular and lymphovascular invasion in early lung cancer. Asian Cardiovascular and Thoracic Annals, 22(1), pp. 55-64.

19

Baird, Anne-Marie, O'Byrne, Ken, & Gray, Steven (2014) Reactive oxygen species and reactive nitrogen species in epigenetic modifications. In Laher, I (Ed.) Systems biology of free radicals and antioxidants. Springer, Germany, pp. 437-455.

5

Douillard, Jean-Yves, Pirker, Robert, O'Byrne, Ken, Kerr, Keith, Stoerkel, Stephan, von Heydebreck, Anja, et al. (2014) Relationship between EGFR expression, EGFR mutation status, and the efficacy of chemotherapy plus Cetuximab in FLEX study patients with advanced non-small-cell lung cancer. Journal of Thoracic Oncology, 9(5), pp. 717-724.

37

38

O'Grady, Shane, Finn, Stephen, Cuffe, Sinead, Richard, Derek, O'Byrne, Ken, & Barr, Martin (2014) The role of DNA repair pathways in cisplatin resistant lung cancer. Cancer Treatment Reviews, 40(10), pp. 1161-1170.

84

76

Kerr, Keith, Bubendorf, Lukas, Edelman, Martin, Marchetti, A., Mok, Tony, Novello, S., et al. (2014) Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. Annals of Oncology, 25(9), pp. 1681-1690.

165

143

Heavey, Susan, Godwin, Peter, Baird, Anne-Marie, Barr, Martin, Umezawa, Kazuo, Cuffe, Sinead, et al. (2014) Strategic targeting of the PI3K-NFkB axis in cisplatin-resistant NSCLC. Cancer Biology and Therapy, 15(10), pp. 1367-1377.

15

12

Heavey, Susan, O'Byrne, Ken, & Gately, Kathy (2014) Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC. Cancer Treatment Reviews, 40(3), pp. 445-456.

77

81

Cathcart, Mary-Clare, Gately, Kathy, Cummins, Robert, Drakeford, Clive, Kay, Elaine, O'Byrne, Ken, et al. (2014) Thromboxane synthase expression and correlation with VEGF and angiogenesis in non-small cell lung cancer. Biochimica et Biophysica Acta - Molecular Basis of Disease, 1842(5), pp. 747-755.

16

18

Osman, Nemer, Elamin, Yasir, Rafee, Shereen, O'Brien, Cathal, Stassen, Leo, Timon, Conrad, et al. (2014) Weekly cisplatin concurrently with radiotherapy in head and neck squamous cell cancer: a retrospective analysis of a tertiary institute experience. European Archives of Oto-Rhino-Laryngology, 271(8), pp. 2253-2259.

10

8

Barr, Martin P., Alcock, Leah C., Stallings, Raymond L., Toomey, Sinead, Carr, Aoife, Hennessy, Bryan T., et al. (2013) Chromosomal and mutational analysis of the cisplatin resistant phenotype in NSCLC cells. In 15th World Conference on Lung Cancer, 2013-10-27 - 2013-10-30.

26

Adams, Mark N., Leong, Vincent, Paquet, Nicolas, Bolderson, Emma, Fennell, Dean A., O'Byrne, Kenneth, et al. (2013) HSSB1: An essential regulator of genomic integrity in lung cancer. In 15th World Conference on Lung Cancer, 2013-10-27 - 2013-10-30.

33

Rausch, Raya, Barr, Martin P., Thomale, Juergen, Richard, Derek, & O'Byrne, Kenneth (2013) PARP inhibition increases sensitivity of NSCLC cells to cisplatin. In 15th World Conference on Lung Cancer, 2013-10-27 - 2013-10-30.

29

Baird, Anne-Marie, Godwin, Peter, Heavey, Susan, Umezawa, Kazuo, Barr, Martin, Richard, Derek, et al. (2013) Targeting NF-κB regulated pathways to overcome cisplatin resistance in non small cell lung cancer. In 15th World Conference on Lung Cancer, 2013-10-27 - 2013-10-30.

32

Godwin, P., Baird, A.M., Heavey, S., Barr, M.P., O'Byrne, K.J., & Gately, K. (2013) Targeting nuclear factor-kappa B to overcome resistance to chemotherapy. Frontiers in Oncology, 3, 120-1---10.

939

115

Shaw, Alice, Kim, Dong-Wan, Nakagawa, Kazuhiko, Seto, Takashi, Crino, Lucio, Ahn, Myung-Ju, et al. (2013) Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. The New England Journal of Medicine, 368(25), pp. 2385-2394.

2,244

2,097

Baird, Anne-Marie, O'Byrne, Kenneth, & Gray, Steven (2013) Epigenetic regulation of chemokine/chemokine receptor expression. Methods in Molecular Biology, 1013, pp. 185-201.

Gao, Yun, Baird, Anne-Marie, Barr, Martin, Gately, Kathy, O'Byrne, Kenneth, & Gray, Steven (2013) Epigenetic therapy for cisplatin resistance in non-small-cell lung cancer: the way forward? [Editorial]. Lung Cancer Management, 2(1), pp. 1-4.

Manente, Arcangela Gabriella, Valenti, D., Pinton, Giulia, Jithesh, P.V., Daga, Antonio, Rossi, L., et al. (2013) Estrogen receptor beta activation impairs mitochondrial oxidative metabolism and affects malignant mesothelioma cell growth in vitro and in vivo. Oncogenesis, 2, Article number: e72 1-10.

22

25

Barr, Martin, Gray, Steven, Hoffmann, Andreas, Hilger, Ralf, Thomale, Juergen, O'Flaherty, John, et al. (2013) Generation and characterisation of cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature. PLoS One, 8(1), pp. 1-19.

67

150

129

Jenkins, Glenn, O'Byrne, Ken, Panizza, Ben, & Richard, Derek (2013) Genome stability pathways in head and neck cancers. International Journal of Genomics, 2013, Article number: 464720 1-19.

113

12

11

Rani, Sweti, Gately, Kathy, Crown, John, O'Byrne, Kenneth, & O'Driscoll, Lorraine (2013) Global analysis of serum microRNAs as potential biomarkers for lung adenocarcinoma. Cancer Biology and Therapy, 14(12), pp. 1104-1112.

48

40

Ashton, Nicholas, Bolderson, Emma, Cubeddu, Liza, O'Byrne, Ken, & Richard, Derek (2013) Human single-stranded DNA binding proteins are essential for maintaining genomic stability. BMC Molecular Biology, 14, pp. 1-20.

50

40

38

Baird, Anne-Marie, Leonard, Jennifer, Naicker, Krisha, Kilmartin, Lisa, O'Byrne, Kenneth, & Gray, Steven (2013) IL-23 is pro-proliferative, epigenetically regulated and modulated by chemotherapy in non-small cell lung cancer. Lung Cancer, 79(1), pp. 83-90.

20

17

Baird, Anne-Marie, Dockry, Eilis, Daly, Anne, Stack, Emma, Doherty, Derek, O'Byrne, Ken, et al. (2013) IL-23R is epigenetically regulated and modulated by chemotherapy in Non-Small Cell Lung Cancer. Frontiers in Oncology, 3, Article number: 162 1-9.

92

11

5

Baird, Anne-Marie, Gray, Steven, & O'Byrne, Kenneth (2013) Inflammation in lung carcinogenesis. In Gately, K (Ed.) Lung cancer: a comprehensive overview. Nova Science Publishers, United States, pp. 191-214.

Wright, Casey, Kirschner, Michaela, Cheng, Yuen Yee, O'Byrne, Kenneth, Gray, Steven, Schelch, Karin, et al. (2013) Long Non Coding RNAs (lncRNAs) are dysregulated in Malignant Pleural Mesothelioma (MPM). PLoS One, 8(8), Article number: e70940 1-12.

148

22

18

Treasure, Tom, Utley, Martin, & O'Byrne, Kenneth (2013) MARS: A sense of perspective and an inconvenient truth [Letters to the Editor]. Journal of Thoracic Oncology, 8(5), e48-e49.

12

11

Barr, Martin, Gray, Steven, Fennell, Dean, O'Leary, John, Richard, Derek, Thomale, Juergen, et al. (2013) MicroRNA profiling and cisplatin-DNA interactions in an isogenic model of cisplatin resistant NSCLC cell lines [Conference Abstract]. Lung Cancer, 79(S1), S1-S1.

Barr, Martin & O'Byrne, Kenneth (2013) Molecular mechanisms of cisplatin resistance in lung cancer. In Gately, K (Ed.) Lung cancer: a comprehensive overview. Nova Science Publishers, United States, pp. 171-190.

Sequist, Lecia, Yang, James Chih-Hsin, Yamamoto, Nobuyuki, O'Byrne, Kenneth, Hirsh, Vera, Mok, Tony, et al. (2013) Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma With EGFR mutations. Journal of Clinical Oncology, 31(27), pp. 3327-3334.

1,797

1,684

Riley, J., Hutchinson, R., McArt, Darragh, Crawford, N., Holohan, Caitriona, Paul, Ian, et al. (2013) Prognostic and therapeutic relevance of FLIP and procaspase-8 overexpression in non-small cell lung cancer. Cell Death and Disease, 4, Article number: e951 1-10.

57

38

37

Yuen, Hiu-Fung, Gunasekharan, Vignesh-Kumar, Chan, Ka-Kui, Zhang, Shu-Dong, Platt-Higgins, Angela, Gately, Kathy, et al. (2013) RanGTPase: A candidate for Myc-mediated cancer progression. Journal of the National Cancer Institute, 105(7), pp. 475-488.

23

20

Cathcart, Mary-Clare, O'Byrne, Kenneth, & Pidgeon, Graham (2013) The role of the arachidonic acid signalling pathway in NSCLC development and progression: novel targets for therapeutic intervention. In Gately, K (Ed.) Lung cancer: a comprehensive overview. Nova Science Publishers, United States, pp. 275-304.

Al-Alao, Bassel, O'Callaghan, D., Gately, Kathy, Nicholson, S., Coate, L., O'Connell, F., et al. (2013) Surgical resection for non-small cell lung cancer: clinical features and outcomes for a consecutive series at an Irish tertiary referral centre. Irish Journal of Medical Science, 182(2), pp. 217-225.

5

Yang, James Chih-Hsin, Hirsh, Vera, Schuler, Martin, Yamamoto, Nobuyuki, O'Byrne, Kenneth, Mok, Tony, et al. (2013) Symptom control and quality of life in LUX-lung 3: A phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. Journal of Clinical Oncology, 31(27), pp. 3342-3350.

234

199

Heavey, Susan, O'Byrne, Kenneth, & Gately, Kathy (2013) Targeted therapies in non-small cell lung cancer. In Gately, K (Ed.) Lung cancer: a comprehensive overview. Nova Science Publishers, United States, pp. 141-170.

Nicolson, Marianne, Fennell, Dean, Ferry, David, O'Byrne, Kenneth, Shah, Riyaz, Potter, Vanessa, et al. (2013) Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non-small-cell lung cancer in a prospective blinded assessment phase II clinical trial. Journal of Thoracic Oncology, 8(7), pp. 930-939.

46

44

Paul, Ian, Chacko, A., Stasik, Izabela, Busacca, Sara, Crawford, N., McCoy, F., et al. (2012) Acquired differential regulation of caspase-8 in cisplatin-resistant non-small-cell lung cancer. Cell Death and Disease, 3, Article number: e449 1-9.

60

16

20

Dowling, Paul, Clarke, Colin, Hennessy, Kim, Torralbo-Lopez, Beatriz, Ballot, Jo, Crown, John, et al. (2012) Analysis of acute-phase proteins, AHSG, C3, CLI, HP and SAA, reveals distinctive expression patterns associated with breast, colorectal and lung cancer. International Journal of Cancer, 131(4), pp. 911-923.

46

41

Brodowicz, Thomas, O'Byrne, Kenneth, & Manegold, Christian (2012) Bone matters in lung cancer. Annals of Oncology, 23(9), pp. 2215-2222.

20

40

35

Busacca, Sara, Sheaff, Michael, Arthur, Kenneth, Gray, Steven, O'Byrne, Kenneth, Richard, Derek, et al. (2012) BRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma. Journal of Pathology, 227(2), pp. 200-208.

15

17

O'Flaherty, John, Barr, Martin, Fennell, Dean, Richard, Derek, Reynolds, John, O'Leary, John, et al. (2012) The cancer stem-cell hypothesis: Its emerging role in lung cancer biology and its relevance for future therapy. Journal of Thoracic Oncology, 7(12), pp. 1880-1890.

83

77

O'Flaherty, John, Gray, Steven, Richard, Derek, Fennell, Dean, O'Leary, John, Blackhall, Fiona, et al. (2012) Circulating tumour cells, their role in metastasis and their clinical utility in lung cancer. Lung Cancer, 76(1), pp. 19-25.

117

104

Collins, Ian, King, F., & O'Byrne, Kenneth (2012) Cost impact of trastuzumab prescribing in the treatment of advanced Her2 positive gastric cancer in Ireland [Letter to the Editor]. Irish Journal of Medical Science, 181(3), pp. 451-452.

1

Cathcart, Mary-Clare, O'Byrne, Kenneth, Reynolds, John, O'Sullivan, Jacintha, & Pidgeon, Graham (2012) COX-derived prostanoid pathways in gastrointestinal cancer development and progression: Novel targets for prevention and intervention. Biochimica et Biophysica Acta - Reviews on Cancer, 1825(1), pp. 49-63.

37

36

30

Pirker, Robert, Pereira, Jose, von Pawel, J, Krzakowski, Maciej, Ramlau, R., Park, Keunchil, et al. (2012) EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer : analysis of data from the phase 3 FLEX study. The Lancet Oncology, 13(1), pp. 33-42.

406

374

Reynolds, John, Donohoe, Claire, McGillycuddy, Erin, Ravi, Narayanasamy, O'Toole, Dermot, O'Byrne, Kenneth, et al. (2012) Evolving progress in oncologic and operative outcomes for esophageal and junctional cancer: Lessons from the experience of a high-volume center. Journal of Thoracic and Cardiovascular Surgery, 143(5), pp. 1130-1137.

28

24

Gray, Steven, Baird, Anne-Marie, O'Kelly, Fardod, Nikolaidis, George, Almgren, Malin, Meunier, Armelle, et al. (2012) Gemcitabine reactivates epigenetically silenced genes and functions as a DNA methyltransferase inhibitor. International Journal of Molecular Medicine, 30(6), pp. 1505-1511.

208

21

20

Gately, Kathy, Al-Alao, Bassel, Dhillon, Tony, Mauri, Francesco, Cuffe, Sinead, Seckl, Michael, et al. (2012) Overexpression of the mammalian target of rapamycin (mTOR) and angioinvasion are poor prognostic factors in early stage NSCLC: A verification study. Lung Cancer, 75(2), pp. 217-222.

19

16

Fennell, Dean, McDowell, Cliona, Busacca, Sara, Webb, Glen, Moulton, Brian, Cakana, Andrew, et al. (2012) Phase II clinical trial of first or second-line treatment with Bortezomib in patients with malignant pleural mesothelioma. Journal of Thoracic Oncology, 7(9), pp. 1466-1470.

35

34

Pirker, Robert, Pereira, Jose, Szczesna, A., von Pawel, J, Krzakowski, Maciej, Ramlau, R., et al. (2012) Prognostic factors in patients with advanced non-small cell lung cancer: Data from the phase III FLEX study. Lung Cancer, 77(2), pp. 376-382.

40

35

Scoccianti, Chiara, Vesin, Aurelien, Martel, Ghislaine, Olivier, Magali, Brambilla, Elisabeth, Timsit, Jean-Francois, et al. (2012) Prognostic value of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer: the EUELC cohort. European Respiratory Journal, 40(1), pp. 177-184.

57

48

Yuen, Hiu-Fung, Chan, Ka-Kui, Grills, Claire, Murray, James, Platt-Higgins, Angela, Eldin, Osama, et al. (2012) Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways. Clinical Cancer Research, 18(2), pp. 380-391.

40

41

Blayney, Jaine, Ceresoli, Giovanni, Castagneto, Bruno, O'Brien, Mary, Hasan, Baktiar, Sylvester, Richard, et al. (2012) Response to chemotherapy is predictive in relation to longer overall survival in an individual patient combined-analysis with pleural mesothelioma. European Journal of Cancer, 48(16), pp. 2983-2992.

19

17

Gately, Kathy, O'Flaherty, John, Cappuzzo, Frederico, Pirker, Robert, Kerr, Keith, & O'Byrne, Kenneth (2012) The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC. Journal of Clinical Pathology, 65(1), pp. 1-7.

31

29

Naidoo, J., O'Toole, Dermot, Kennedy, M. John, Reynolds, John, O'Connor, M., & O'Byrne, Kenneth (2012) A single institution experience of streptozocin/fluorouracil combination chemotherapy: a case series. Irish Journal of Medical Science, 181(2), pp. 211-214.

4

Pirker, Robert, Stoerkel, Stephan, von Heydebreck, Anja, Celik, Ilhan, & O'Byrne, Kenneth (2012) A STEPP too far for FLEX? - Authors' reply. The Lancet Oncology, 13(2), e51-e51.

Spigel, David, Edelman, Martin, Mok, Tony, O'Byrne, Kenneth, Paz-Ares, Luis, Yu, Wei, et al. (2012) Treatment rationale study design for the MetLung trial : a randomized, double-blind phase III study of onartuzumab (MetMAb) in combination with erlotinib versus erlotinib alone in patients who have received standard chemotherapy for stage IIIB or IV. Clinical Lung Cancer, 13(6), pp. 500-504.

73

65

Hurwitz, Jane, Stasik, Izabela, Kerr, Emma, Holohan, Caitriona, Redmond, Kelly, McLaughlin, Kirsty, et al. (2012) Vorinostat/SAHA-induced apoptosis in malignant mesothelioma is FLIP/caspase 8-dependent and HR23B-independent. European Journal of Cancer, 48(7), pp. 1096-1107.

33

31

Gately, Kathy, Kerr, Keith, & O'Byrne, Kenneth (2011) Design, construction, and analysis of cell line arrays and tissue microarrays for gene expression analysis. Methods in Molecular Biology, 784, pp. 139-153.

7

6

O'Byrne, Kenneth, Baird, Anne-Marie, Kilmartin, Lisa, Leonard, Jennifer, Sacevich, Calen, & Gray, Steven (2011) Epigenetic regulation of glucose transporters in non-small cell lung cancer. Cancers, 3(2), pp. 1550-1565.

44

Baird, Anne-Marie, Gray, Steven, & O'Byrne, Kenneth (2011) Epigenetics underpinning the regulation of the CXC (ELR+) chemokines in non-small cell lung cancer. PLoS One, 6(1), Article number: e14593 1-11.

48

32

28

Cathcart, Mary-Clare, Gately, Kathy, Cummins, Robert, Kay, Elaine, O'Byrne, Kenneth, & Pidgeon, Graham (2011) Examination of thromboxane synthase as a prognostic factor and therapeutic target in non-small cell lung cancer. Molecular Cancer, 10, Article number: 25 1-14.

29

40

37

Treasure, Tom, Lang-Lazdunski, Loic, Waller, David, Bliss, Judith, Tan, Carol, Entwisle, James, et al. (2011) Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. The Lancet Oncology, 12(8), pp. 763-772.

395

362

Shukla, Arti, Barrett, Trisha, MacPherson, Maximilian, Hillegass, Jedd, Fukagawa, Naomi, Swain, William, et al. (2011) An extracellular signal-regulated kinase 2 survival pathway mediates resistance of human mesothelioma cells to asbestos-induced injury. American Journal of Respiratory Cell and Molecular Biology, 45(5), pp. 906-914.

8

Gatzemeier, Ulrich, von Pawel, J, Vynnychenko, Ihor, Zatloukal, Petr, De Marinis, Filippo, Eberhardt, Wilfried, et al. (2011) First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study. The Lancet Oncology, 12(1), pp. 30-37.

99

86

Baird, Anne-Marie, Gray, Steven, & O'Byrne, Kenneth (2011) IL-20 is epigenetically regulated in NSCLC and down regulates the expression of VEGF. European Journal of Cancer, 47(12), pp. 1908-1918.

20

19

Bliss, Judith M., Coombes, Gill, Darlison, Liz, Edwards, John, Entwisle, James, Kilburn, Lucy S., et al. (2011) The MARS feasibility trial : Conclusions not supported by data - Authors' reply. The Lancet Oncology, 12(12), pp. 1094-1095.

3

O'Byrne, Kenneth, Gatzemeier, Ulrich, Bondarenko, Igor, Barrios, Carlos, Eschbach, Corinna, Martens, Uwe, et al. (2011) Molecular biomarkers in non-small-cell lung cancer : a retrospective analysis of data from the phase 3 FLEX study. The Lancet Oncology, 12(8), pp. 795-805.

161

146

Paul, Ian, Savage, Kienan, Blayney, Jaine, Lamers, Elisabeth, Gately, Kathy, Kerr, Keith, et al. (2011) PARP inhibition induces BAX/BAK-independent synthetic lethality of BRCA1-deficient non-small cell lung cancer. Journal of Pathology, 224(4), pp. 564-574.

25

26

Cathcart, Mary-Clare, Gray, Steven, Baird, Anne-Marie, Boyle, Elaine, Gately, Kathy, Kay, Elaine, et al. (2011) Prostacyclin synthase expression and epigenetic regulation in nonsmall cell lung cancer. Cancer, 117(22), pp. 5121-5132.

15

13

Easty, David, Gray, Steven, O'Byrne, Kenneth, O'Donnell, Dearbhaile, & Bennett, Dorothy (2011) Receptor tyrosine kinases and their activation in melanoma. Pigment Cell and Melanoma Research, 24(3), pp. 446-461.

49

47

Gately, Kathy, Collins, Ian, Forde, Lydia, Al-Alao, Bassel, Young, Vincent, Gerg, Michael, et al. (2011) A role for IGF-1R-targeted therapies in small-cell lung cancer? Clinical Lung Cancer, 12(1), pp. 38-42.

8

7

O'Byrne, Kenneth, Barr, Martin, & Gray, Steven (2011) The role of epigenetics in resistance to cisplatin chemotherapy in lung cancer. Cancers, 3(1), pp. 1426-1453.

56

25

Reynolds, John, Ravi, Narayanasamy, Muldoon, Cian, Larkin, John, Rowley, Suzanne, O'Byrne, Kenneth, et al. (2010) Differential pathologic variables and outcomes across the spectrum of adenocarcinoma of the esophagogastric junction. World Journal of Surgery, 34(12), pp. 2821-2829.

26

23

Collins, Ian, Nicholson, Siobhan, & O'Byrne, Kenneth (2010) A lung cancer responding to hormonal therapy. Journal of Thoracic Oncology, 5(5), pp. 749-750.

2

1

Stahel, Rolf, Baas, Paul, Faivre-Finn, Corinne, Dooms, Christophe, Passlick, Bernward, Mazières, Julien, et al. (2010) Meeting report : 2nd meeting of the European Thoracic Oncology Platform (ETOP). Lung Cancer, 68(1), pp. 121-124.

Van Den Berg, M, Brokx, Hes, Vesin, Aurelien, Field, J., Brambilla, C., Meijer, Chris, et al. (2010) Prognostic value of hTERT mRNA expression in surgical samples of lung cancer patients: the European Early Lung Cancer Project. International Journal of Oncology, 37(2), pp. 455-461.

8

9

Collins, Ian, Beddy, Peter, & O'Byrne, Kenneth (2010) Radiological response in an incidental meningioma in a patient treated with chemotherapy combined with CP-751,871, an IGF-1R inhibitor [Letter to the Editor]. Acta Oncologica, 49(6), pp. 872-874.

8

6

O'Callaghan, D., O'Donnell, D., O'Connell, Finbarr, & O'Byrne, Kenneth (2010) The role of inflammation in the pathogenesis of non-small cell lung cancer. Journal of Thoracic Oncology, 5(12), pp. 2024-2036.

135

121

Cathcart, Mary-Clare, Reynolds, John, O'Byrne, Kenneth, & Pidgeon, Graham (2010) The role of prostacyclin synthase and thromboxane synthase signaling in the development and progression of cancer. Biochimica et Biophysica Acta - Reviews on Cancer, 1805(2), pp. 153-166.

55

46

Lawless, M., O'Byrne, Kenneth, & Gray, Steven (2010) Targeting oxidative stress in cancer. Expert Opinion on Therapeutic Targets, 14(11), pp. 1225-1245.

47

40

Pirker, Robert, Pereira, Jose, Szczesna, Aleksandra, von Pawel, J, Krzakowski, Maciej, Ramlau, Rodryg, et al. (2009) Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. The Lancet, 373(9674), pp. 1525-1531.

1,173

1,028

Power, D., Galvin, David, Cuffe, Sinead, McVey, Gerald, Mulholland, Paul, Farrelly, Cormac, et al. (2009) Cisplatin and gemcitabine in the management of metastatic penile cancer. Urologic Oncology: Seminars and Original Investigations, 27(2), pp. 187-190.

16

17

Field, J., Liloglou, T., Niaz, A., Bryan, J., Gosney, J., Giles, T., et al. (2009) EUELC project : a multi-centre, multipurpose study to investigate early stage NSCLC, and to establish a biobank for ongoing collaboration. European Respiratory Journal, 34(6), pp. 1477-1486.

13

Maher, Stephen, Gillham, Charles, Duggan, Shane, Smyth, Paul, Miller, Nicola, Muldoon, Cian, et al. (2009) Gene expression analysis of diagnostic biopsies predicts pathological response to neoadjuvant chemoradiotherapy of esophageal cancer. Annals of Surgery, 250(5), pp. 729-736.

2

49

Lawless, M., O'Byrne, Kenneth, & Gray, Steven (2009) Histone deacetylase inhibitors target diabetes via chromatin remodeling or as chemical chaperones? Current Diabetes Reviews, 5(3), pp. 201-209.

13

12

Gray, Steven, Fennell, Dean, O'Byrne, Kenneth, & Mutti, Luciano (2009) In arrayed ranks array technology in the study of mesothelioma steven. Journal of Thoracic Oncology, 4(3), pp. 411-425.

14

11

Lawless, Matthew, O'Byrne, Kenneth, & Gray, Steven (2009) Oxidative stress induced lung cancer and COPD: opportunities for epigenetic therapy. Journal of Cellular and Molecular Medicine, 13(9a), pp. 2800-2821.

54

55

Wilson, T., Redmond, Kelly, McLaughlin, Kirsty, Crawford, N., Gately, Kathy, O'Byrne, Kenneth, et al. (2009) Procaspase 8 overexpression in non-small-cell lung cancer promotes apoptosis induced by FLIP silencing. Cell Death and Differentiation, 16(10), pp. 1352-1361.

33

34

Gray, Steven, Al-Sarraf, Nael, Baird, Anne-Marie, Cathcart, Mary-Clare, McGovern, E., & O'Byrne, Kenneth (2009) Regulation of EP receptors in non-small cell lung cancer by epigenetic modifications. European Journal of Cancer, 45(17), pp. 3087-3097.

20

Lilenbaum, Rogerio, Villaflor, Victoria, Langer, Corey, O'Byrne, Kenneth, O'Brien, Mary, Ross, Helen, et al. (2009) Single-agent versus combination chemotherapy in patients with advanced non-small cell lung cancer and a performance status of 2: prognostic factors and treatment selection based on two large randomized clinical trials. Journal of Thoracic Oncology, 4(7), pp. 869-874.

56

54

Lawless, M., Norris, S., O'Byrne, Kenneth, & Gray, Steven (2009) Targeting histone deacetylases for the treatment of disease. Journal of Cellular and Molecular Medicine, 13(5), pp. 826-852.

37

31

Lawless, M., Norris, S., O'Byrne, Kenneth, & Gray, Steven (2009) Targeting histone deacetylases for the treatment of immune, endocrine and metabolic disorders. Endocrine, Metabolic and Immune Disorders - Drug Targets, 9(1), pp. 84-107.

Fennell, Dean, Guadino, Giovanni, O'Byrne, Kenneth, Mutti, Luciano, & Van Meerbeeck, Jan (2008) Advances in the systemic therapy of malignant pleural mesothelioma. Nature Reviews Cardiology, 5(3), pp. 136-147.

108

107

Power, D., Mulholland, P., & O'Byrne, Kenneth (2008) AIDS-related Kaposi's Sarcoma in a patient with a normal CD4 count [Letter]. Clinical Oncology, 20(1), p. 97.

3

2

Cathcart, Mary-Clare, Tamosiuniene, Rasa, Chen, Gang, Neilan, Tomas, Bradford, Aidan, O'Byrne, Kenneth, et al. (2008) Cyclooxygenase-2-linked attenuation of hypoxia-induced pulmonary hypertension and intravascular thrombosis. Journal of Pharmacology and Experimental Therapeutics, 326(1), pp. 51-58.

23

Langer, Corey, O'Byrne, Kenneth, Socinski, Mark, Mikhailov, Sergei, Lesniewski-Kmak, Krzysztof, Smakal, Martin, et al. (2008) Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer. Journal of Thoracic Oncology, 3(6), pp. 623-630.

143

134

Gillham, Charles, Aherne, N., Rowley, Suzanne, Moore, J., Hollywood, Donal, O'Byrne, Kenneth, et al. (2008) Quality of life and survival in patients treated with radical chemoradiation alone for oesophageal cancer. Clinical Oncology, 20(3), pp. 227-233.

11

9

Rosell, R., Robinet, G., Szczesna, A., Ramlau, R., Constenla, M., Mennecier, B., et al. (2008) Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Annals of Oncology, 19(2), pp. 362-369.

241

208

Gray, Steven, Al-Sarraf, Nael, Baird, Anne-Marie, Gately, Kathy, McGovern, Elish, & O'Byrne, Kenneth (2008) Transcriptional regulation of IRS5/DOK4 expression in non-small-cell lung cancer cells. Clinical Lung Cancer, 9(6), pp. 367-374.

4

3

Sherwood, B., Colquhoun, A., Richardson, Donna, Bowman, K., O'Byrne, Kenneth, Kockelbergh, R., et al. (2007) Carbonic anhydrase IX expression and outcome after radiotherapy for muscle-invasive bladder cancer. Clinical Oncology, 19(10), pp. 777-783.

11

Roison, C, Doherty, Colin, Beddy, Peter, & O'Byrne, Kenneth (2007) Chemotherapy induced reversible posterior leukoencephalopathy syndrome. Lung Cancer, 56(3), pp. 459-463.

30

O'Byrne, Kenneth, Danson, Sarah, Dunlop, David, Botwood, Nick, Taguchi, Fumiko, Carbone, David, et al. (2007) Combination therapy with gefitinib and rofecoxib in patients with platinum-pretreated relapsed non-small-cell lung cancer. Journal of Clinical Oncology, 25(22), pp. 3266-3273.

39

38

Le, Quynh-Thu, Kong, Christina, Lavori, Phillip, O'Byrne, Kenneth, Erler, Janine, Huang, Xin, et al. (2007) Expression and prognostic significance of a panel of tissue hypoxia markers in head-and-neck squamous cell carcinomas. International Journal of Radiation: Oncology - Biology - Physics, 69(1), pp. 167-175.

95

88

Pidgeon, Graham, Lysaght, Joanne, Krishnamoorthy, Sriram, Reynolds, John, O'Byrne, Kenneth, Nie, Daotai, et al. (2007) Lipoxygenase metabolism: roles in tumor progression and survival. Cancer and Metastasis Reviews, 26(3 - 4), pp. 503-524.

195

179

Reynolds, John, Muldoon, Cian, Hollywood, Donal, Ravi, Narayanasamy, Rowley, Suzanne, O'Byrne, Kenneth, et al. (2007) Long-term outcomes following neoadjuvant chemoradiotherapy for esophageal cancer. Annals of Surgery, 245(5), pp. 707-716.

117

105

Gillham, Charles, Lucey, Julie, Keogan, Mary, Duffy, G, Malik, Vinod, Raouf, A, et al. (2006) 18FDG uptake during induction chemoradiation for oesophageal cancer fails to predict histomorphological tumour response. British Journal of Cancer, 95(9), pp. 1174-1179.

101

92

Edwards, John, Swinson, Daniel, Jones, J, Waller, David, & O'Byrne, Kenneth (2006) EGFR expression : associations with outcome and clinicopathological variables in malignant pleural mesothelioma. Lung Cancer, 54(3), pp. 399-407.

69

62

Le, Quynh-Thu, Chen, Eunice, Salim, Ali, Cao, Hongbin, Kong, Christina, Whyte, Richard, et al. (2006) An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. Clinical Cancer Research, 12(5), pp. 1507-1514.

169

157

Swinson, Daniel & O'Byrne, Kenneth (2006) Interactions between hypoxia and epidermal growth factor receptor in non-small-cell-lung cancer. Clinical Lung Cancer, 7(4), pp. 250-256.

49

47

Booton, R, Lorigan, Paul, Anderson, H, Baka, S, Ashcroft, L, Nicholson, Marianne, et al. (2006) A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/ cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer : a randomised multicentre trial of the British Thoracic Oncolog. Annals of Oncology, 17(7), pp. 1111-1119.

60

52

Sharma, R, Steward, William, Daines, C, Knight, R, O'Byrne, Kenneth, & Dalgleish, A (2006) Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide: Phase I clinical trial of three dosing schedules in patients with solid malignancies. European Journal of Cancer, 42(14), pp. 2318-2325.

49

43

Burdett, Sarah, Stewart, Lesley, Pignon, Jean-Pierre, Sedrakyan, Artyom, & O'Byrne, Kenneth (2005) Chemotherapy in non-small cell lung cancer: An update of an individual patient data-based meta-analysis [13] (reply to the editor). The Journal of Thoracic and Cardiovascular Surgery, 129(5), pp. 1205-1206.

14

12

Richardson, C, Richardson, D, Swinson, Daniel, Swain, W, Cox, G, & O'Byrne, Kenneth (2005) Cyclooxygenase-2 protein levels are independent of epidermal growth factor receptor expression or activation in operable non-small cell lung cancer. Lung Cancer, 48(1), pp. 47-57.

20

Sutton, Christopher, O'Byrne, Kenneth, Goddard, Jonathan, Marshall, Leslie-Jayne, Jones, J, Garcea, Guiseppe, et al. (2005) Expression of thrombospondin-1 in resected colorectal liver metastases predicts poor prognosis. Clinical Cancer Research, 11(18), pp. 6567-6573.

24

22

Le, Quynh-Thu, Shi, Gongyi, Cao, Hongbin, Nelson, Daniel, Wang, Yingyun, Chen, Eunice, et al. (2005) Galectin-1 : a link between tumor hypoxia and tumor immune privilege. Journal of Clinical Oncology, 23(35), pp. 8932-8941.

188

169

Welsh, Tomas, Green, Ruth, Richardson, Donna, Waller, David, O'Byrne, Kenneth, & Bradding, Peter (2005) Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. Journal of Clinical Oncology, 23(35), pp. 8959-8967.

232

212

Bissett, Donald, O'Byrne, Kenneth, von Pawel, J, Gatzemeier, Ulrich, Price, Allan, Nicolson, Marianne, et al. (2005) Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer. Journal of Clinical Oncology, 23(4), pp. 842-849.

151

132

Shah, Amit, Swain, William, Richardson, Donna, Edwards, John, Stewart, Duncan, Richardson, Catherine, et al. (2005) Phospho-Akt expression is associated with a favorable outcome in non-small cell lung cancer. Clinical Cancer Research, 11(8), pp. 2930-2936.

79

77

DeCatris, Marios, Sundar, Santhanam, & O'Byrne, Kenneth (2005) Platinum-based chemotherapy in metastatic breast cancer : the Leicester (UK) experience. Clinical Oncology, 17(4), pp. 249-257.

9

Marty, Michael, Cognetti, Francesco, Maraninchi, Dominique, Snyder, Raymond, Mauriac, Louis, Tubiana-Hulin, Michele, et al. (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment : the M77001 study group. Journal of Clinical Oncology, 23(19), pp. 4265-4274.

1,242

1,088

Martin-Ucar, Antonio, Waller, David, Atkins, Jane, Swinson, Daniel, O'Byrne, Kenneth, & Peake, Mick (2004) The beneficial effects of specialist thoracic surgery on the resection rate for non-small-cell lung cancer. Lung Cancer, 46(2), pp. 227-232.

59

53

Pilling, John, Stewart, Duncan, Martin-Ucar, Antonio, Muller, S, O'Byrne, Kenneth, & Waller, David (2004) The case for routine cervical mediastinoscopy prior to radical surgery for malignant pleural mesothelioma. European Journal of Cardio-thoracic Surgery, 25(4), pp. 497-501.

44

42

O'Byrne, Kenneth, Edwards, John, & Waller, David (2004) Clinico-pathological and biological prognostic factors in pleural malignant mesothelioma. Lung Cancer, 45(SUPPL.), S45-S48.

34

32

Swinson, D, Cox, G, & O'Byrne, Kenneth (2004) Coexpression of epidermal growth factor receptor with related factors is associated with a poor prognosis in non-small-cell lung cancer. British Journal of Cancer, 91(7), pp. 1301-1307.

47

Stewart, Duncan, Martin-Ucar, Antonio, Pilling, John, Edwards, John, O'Byrne, Kenneth, & Waller, David (2004) The effect of extent of local resection on patterns of disease progression in malignant pleural mesothelioma. Annals of Thoracic Surgery, 78(1), pp. 245-252.

51

47

Arun, C, DeCatris, Marios, Hemingway, David, London, N, & O'Byrne, Kenneth (2004) Endothelin-1 is a novel prognostic factor in non-small cell lung cancer. International Journal of Biological Markers, 19(4), pp. 262-267.

21

20

Swinson, Daniel, Jones, J, Cox, Giles, Richardson, Donna, Harris, Adrian, & O'Byrne, Kenneth (2004) Hypoxia-inducible factor-1a in non small cell lung cancer: Relation to growth factor, protease and apoptosis pathways. International Journal of Cancer, 111(1), pp. 43-50.

126

104

Sundar, Santhanam, DeCatris, Marios, & O'Byrne, Kenneth (2004) Management of endocrine resistant breast cancer. Post reproductive health, 10(1), pp. 16-23.

4

Sundar, Santhanam, Symonds, R, DeCatris, Marios, Kumar, D, Osman, A, Vasanthan, Subra, et al. (2004) Phase II trial of Oxaliplatin and 5-Fluorouracil/Leucovorin combination in epithelial ovarian carcinoma relapsing within 2 years of platinum-based therapy. Gynecologic Oncology, 94(2), pp. 502-508.

23

20

DeCatris, Marios, Sundar, Santhanam, & O'Byrne, Kenneth (2004) Platinum-based chemotherapy in metastatic breast cancer : current status. Cancer Treatment Reviews, 30(1), pp. 53-81.

152

133

Sedrakyan, Artyom, vanderMeulen, Jan, O'Byrne, Kenneth, Prendiville, Joseph, Hill, Jennifer, & Treasure, Tom (2004) Postoperative chemotherapy for non-small cell lung cancer: A systematic review and meta-analysis. Journal of Thoracic and Cardiovascular Surgery, 128(3), pp. 414-419.

100

85

Papazisis, K, Habeshaw, T, Miles, David, & O'Byrne, Kenneth (2004) Safety and efficacy of the combination of trastuzumab with docetaxel for HER2-positive women with advanced breast cancer. A review of the existing clinical trials and results of the expanded access programme in the UK. International Journal of Clinical Practice, 58(6), pp. 581-586.

7

6

O'Brien, Mary, Anderson, H, Kaukel, E, O'Byrne, Kenneth, Pawlicki, M, von Pawel, J, et al. (2004) SRL172 (killed Mycobacterium vaccae) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced non-small-cell lung cancer : phase III results. Annals of Oncology, 15(6), pp. 906-914.

96

88

Swinson, Daniel E. B., Jones, J. Louise, Richardson, Donna, Wykoff, Charles, Turley, Helen, Pastorek, Jaromir, et al. (2003) Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer. Journal of Clinical Oncology, 21(3), pp. 473-482.

216

Morgan, Bruno, Thomas, Anne L., Drevs, Joachim, Hennig, Juergin, Buchert, Martin, Jivan, Asvina, et al. (2003) Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: Results from two phase I studies. Journal of Clinical Oncology, 21(21), pp. 3955-3964.

567

Richardson, C. M., Sharma, R. A., Cox, G., & O'Byrne, Kenneth J. (2003) Epidermal growth factor receptors and cyclooxygenase-2 in the pathogenesis of non-small cell lung cancer : potential targets for chemoprevention and systemic therapy. Lung Cancer, 39(1), pp. 1-13.

43

Edwards, J. G., McLaren, J., Jones, J. L., Waller, D. A., & O'Byrne, Kenneth J. (2003) Matrix metalloproteinases 2 and 9 (gelatinases A and B) expression in malignant mesothelioma and benign pleura. British Journal of Cancer : BJC, 88(10), pp. 1553-1559.

61

Danson, S., Middleton, M. R., O'Byrne, Kenneth J., Clemons, M., Ranson, M., Hassan, J., et al. (2003) Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma. Cancer, 98(3), pp. 542-553.

67

Sharma, Ricky A., Decatris, Marios P., Santhanam, Sundar, Roy, Rajarshi, Osman, Ahmed E., Clarke, Christine B., et al. (2003) Reversibility of liver failure secondary to metastatic breast cancer by vinorelbine and cisplatin chemotherapy. Cancer Chemotherapy and Pharmacology, 52(5), pp. 367-370.

12

Edwards, J. G., Swinson, D. E. B., Jones, J. L., Muller, S., Waller, D. A., & O'Byrne, Kenneth J. (2003) Tumor necrosis correlates with angiogenesis and is a predictor of poor prognosis in malignant mesothelioma. Chest, 124(5), pp. 1916-1923.

71

Goddard, J. C., Sutton, C. D., Furness, P. N., Kockelbergh, R. C., & O'Byrne, Kenneth J. (2002) A computer image analysis system for microvessel density measurement in solid tumours. Angiogenesis, 5(1-2), pp. 15-20.

26

O'Byrne, Kenneth J., Thomas, A. L., Sharma, R. A., DeCatris, M., Shields, F., Beare, S., et al. (2002) A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancer. British Journal of Cancer, 87(1), pp. 15-20.

47

Goddard, J. C., Sutton, C. D., Jones, J. L., O'Byrne, Kenneth J., & Kockelbergh, R. C. (2002) Reduced Thrombospondin-1 at presentation predicts disease progression in superficial bladder cancer. European Urology, 42(5), pp. 464-468.

20

Swinson, Daniel E. B., Jones, J. Louise, Richardson, Donna, Cox, Giles, Edwards, John G., & O'Byrne, Kenneth J. (2002) Tumour necrosis is an independent prognostic marker in non-small cell lung cancer : correlation with biological variables. Lung Cancer, 37(3), pp. 235-240.

92

Sharma, Ricky A., Harris, Adrian L., Dalgleish, Angus G., Steward, William P., & O'Byrne, Kenneth J. (2001) Angiogenesis as a biomarker and target in cancer chemoprevention. Lancet Oncology, 2(12), pp. 726-732.

56

Edwards, J. G., Cox, G., Andi, A., Jones, J. L., Walker, R. A., Waller, D. A., et al. (2001) Angiogenesis is an independent prognostic factor in malignant mesothelioma. British Journal of Cancer : BJC, 85(6), pp. 863-868.

68

Santhanam, S. & O'Byrne, Kenneth J. (2001) Antioestrogens and breast cancer. Journal of the British Menopause Society, 7(1), pp. 21-26.

Sharma, Ricky A., Eatock, Martin M., Twelves, Christopher J., Brown, Gill, McLelland, Heather R., Clayton, Kathryn T., et al. (2001) Bioavailability study of oral and intravenous OGT 719, a novel nucleoside analogue with preferential activity in the liver. Cancer Chemotherapy and Pharmacology, 48(3), pp. 197-201.

2

Sharma, Ricky A., Eatock, Martin M., Twelves, Christopher J., Brown, Gill, McLelland, Heather R., Clayton, Kathryn T., et al. (2001) Bioavailability study of oral and intravenous OGT 719, a novel nucleoside analogue with preferential activity in the liver. Cancer Chemotherapy and Pharmacology, 48(3), pp. 197-201.

Cox, G., Jones, J.L., Andi, A., Waller, D.A., & O'Byrne, K.J. (2001) A biological staging model for operable non-small cell lung cancer. Thorax, 56(7), pp. 561-566.

80

O'Byrne, Kenneth J. & Dalgleish, A. G. (2001) Chronic immune activation and inflammation as the cause of malignancy. British Journal of Cancer, 85(4), pp. 473-483.

399

Mortimer, Neil, Hughes, David, & O'Byrne, Kenneth J. (2001) Clinical picture : intramedullary spinal cord metastasis. Lancet Oncology, 2(10), p. 607.

9

Sharma, R.A., Gescher, A.J., O'Byrne, K.J., & Steward, W.P. (2001) Familiar drugs may prevent cancer. Postgraduate Medical Journal, 77(910), pp. 492-497.

9

Cox, G., Vyberg, M., Melgaard, B., Askaa, J., Oster, A., & O'Byrne, Kenneth J. (2001) Herceptest: HER2 expression and gene amplification in non-small cell lung cancer. International Journal of Cancer, 92(4), pp. 480-483.

74

Thomas, Anne L., O'Byrne, Kenneth J., Furber, Lynn, Jeffery, Katie, & Steward, William P. (2001) A phase II study of Caelyx, liposomal doxorubicin : lack of activity in patients with advanced gastric cancer. Cancer Chemotherapy and Pharmacology, 48(4), pp. 266-268.

13

O'Byrne, Kenneth J., Schally, A. V., Thomas, A., Carney, D. N., & Steward, W. P. (2001) Somatostatin, its receptors and analogs, in lung cancer. Chemotherapy, 47(SUP.2), pp. 78-108.

54

Goddard, J. C., Sutton, C. D., Berry, D. P., O'Byrne, Kenneth J., & Kockelbergh, R. C. (2001) The use of microvessel density in assessing human urological tumours. BJU International, 87(9), pp. 866-875.

14

Cox, G., Jones, J. L., Walker, R. A., Steward, W. P., & O'Byrne, Kenneth J. (2000) Angiogenesis and non-small cell lung cancer. Lung Cancer, 27(2), pp. 81-100.

90

Thomas, A.L., O'Byrne, K.J., & Steward, W.P. (2000) Chemotherapy for upper gastrointestinal tumours. Postgraduate Medical Journal, 76(896), pp. 321-327.

5

Braybrooke, Jeremy P., Houlbrook, Sue, Crawley, Judith E., Propper, David J., O'Byrne, Kenneth J., Stratford, Ian J., et al. (2000) Evaluation of the alkaline comet assay and urinary 3-methyladenine excretion for monitoring DNA damage in melanoma patients treated with dacarbazine and tamoxifen. Cancer Chemotherapy and Pharmacology, 45(2), pp. 111-119.

18

Thomas, A. L., Cox, G., Sharma, R. A., Steward, W. P., Shields, F., Jeyapalan, K., et al. (2000) Gemcitabine and paclitaxel associated pneumonitis in non-small cell lung cancer : report of a phase I/II dose-escalating study. European Journal of Cancer, 36(18), pp. 2329-2334.

50

Giatromanolaki, A., Koukourakis, M. I., Sivridis, E., O'Byrne, Kenneth J., Gatter, K. C., & Harris, A. L. (2000) Invading edge vs. inner (edvin) patterns of vascularization : an interplay between angiogenic and vascular survival factors defines the clinical behaviour of non-small cell lung cancer. Journal of Pathology, 192(2), pp. 140-149.

50

Dobbs, Stephen P., Brown, Laurence, Ireland, David, Abrams, Keith R., Murray, J. Cliff, Gatter, Keith, et al. (2000) Platelet-derived endothelial cell growth factor expression and angiogenesis in cervical intraepithelial neoplasia and squamous cell carcinoma of the cervix. Annals of Diagnostic Pathology, 4(5), pp. 286-292.

17

Edwards, J.G., Abrams, K.R., Leverment, JN., Spyt, T.J., Waller, D.A., & O'Byrne, K.J. (2000) Prognostic factors for malignant mesothelioma in 142 patients : validation of CALGB and EORTC prognostic scoring systems. Thorax, 55(9), pp. 731-735.

240

Cox, G., Walker, R. A., Andi, A., Steward, W. P., & O'Byrne, Kenneth J. (2000) Prognostic significance of platelet and microvessel counts in operable non-small cell lung cancer. Lung Cancer, 29(3), pp. 169-177.

68

O'Byrne, Kenneth J., Dalgleish, A. G., Browning, M. J., Steward, W. P., & Harris, A. L. (2000) The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease. European Journal of Cancer, 36(2), pp. 151-169.

164

Cox, G., Jones, J.L., & O'Byrne, K.J. (1999) Expression and prognostic influence of MMP-2, MMP-9 and TIMP-2 in non-small cell lung cancer. Thorax, 54(SUP. 3), A83.

Cox, G., Jones, J.L., & O'Byrne, K.J. (1999) MMP-9 and the epidermal growth factor signal pathway in non-small cell lung cancer. Thorax, 54(SUP. 3), A82.

Koukourakis, M. I., Giatromanolaki, A., O'Byrne, Kenneth J., Jiles, C., Krammer, B., Gatter, K. C., et al. (1999) bcl-2 and c-erbB-2 proteins are involved in the regulation of VEGF and of thymidine phosphorylase angiogenic activity in non-small-cell lung cancer. Clinical and Experimental Metastasis, 17(7), pp. 545-554.

45

Cassidy, Jim, Twelves, Chris, Cameron, David, Steward, William, O'Byrne, Kenneth J., Jodrell, Duncan, et al. (1999) Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients. Cancer Chemotherapy and Pharmacology, 44(6), pp. 453-460.

81

O'Byrne, Kenneth J., Philip, P. A., Propper, D. J., Braybrooke, J. P., Saunders, M. P., Bates, N. P., et al. (1999) A phase II study of the modulation of 5-fluorouracil and folinic acid with high-dose infusional hydroxyurea in metastatic colorectal carcinoma. Annals of Oncology, 10(8), pp. 981-983.

6

O'Byrne, Kenneth J. & Steward, W. P. (1999) The role of chemotherapy in the treatment of adult soft tissue sarcomas. Oncology, 56(1), pp. 13-23.

39

O'Byrne, Kenneth J., Han, C., Mitchell, K., Lane, D., Carmichael, J., Harris, A. L., et al. (1998) Phase II study of liarozole in advanced non-small cell lung cancer. European Journal of Cancer, 34(9), pp. 1463-1466.

11

Joel, S., O'Byrne, Kenneth J., Penson, R., Papamichael, D., Higgins, A., Robertshaw, H., et al. (1998) A randomised, concentration-controlled, comparison of standard (5-day) vs. prolonged (15-day) infusions of etoposide phosphate in small-cell lung cancer. Annals of Oncology, 9(11), pp. 1205-1211.

16

O'Byrne, Kenneth J. & Steward, W. P. (1998) The role of adjuvant chemotherapy in the treatment of adult soft tissue sarcomas. Critical Reviews in Oncology/Hematology, 27(3), pp. 221-227.

11

Katso, R. M. T., Manek, S., O'Byrne, Kenneth J., Playford, M. P., Le Meuth, V., & Ganesan, T. S. (1997) Molecular approaches to diagnosis and management of ovarian cancer. Cancer and Metastasis Reviews, 16(1-2), pp. 81-107.

23

Braybrooke, J. P., O'Byrne, Kenneth J., Saunders, M. P., Propper, D. J., Salisbury, A. J., Boardman, P., et al. (1997) A phase II study of mitomycin C and oral etoposide for advanced adenocarcinoma of the upper gastrointestinal tract. Annals of Oncology, 8(3), pp. 294-296.

6

Giatromanolaki, A., Koukourakis, M. I., Comley, M., Kaklamams, L., Turley, H., O'Byrne, Kenneth J., et al. (1997) Platelet-derived endothelial cell growth factor (thymidine phosphorylase) expression in lung cancer. Journal of Pathology, 181(2), pp. 196-199.

61

Koukourakis, M. I., Giatromanolaki, A., O'Byrne, Kenneth J., Whitehouse, R. M., Talbot, D. C., Gatter, K. C., et al. (1997) Potential role of bcl-2 as a suppressor of tumour angiogenesis in non- small-cell lung cancer. International Journal of Cancer, 74(6), pp. 565-570.

63

Giatromanolaki, A., Koukourakis, M., O'Byrne, Kenneth J., Fox, S., Whitehouse, R., Talbot, D. C., et al. (1996) Prognostic value of angiogenesis in operable non-small cell lung cancer. Journal of Pathology, 179(1), pp. 80-88.

171

O'Byrne, Kenneth J. & Carney, Desmond N. (1996) Radiolabelled somatostatin analogue scintigraphy in oncology. Anti-Cancer Drugs, 7(SUP1), pp. 33-44.

29

O'Byrne, Kenneth J., Goggins, Michael G., McDonald, George S., Daly, Peter A., Kelleher, Dermot P., & Weir, Donald G. (1994) A metastatic neuroendocrine anaplastic small cell tumor in a patient with multiple endocrine neoplasia type 1 syndrome : assessment of disease status and response to doxorubicin, cyclophosphamide, etoposide chemotherapy through scintigraphic imaging with 111In-pentetreotide. Cancer, 74(8), pp. 2374-2378.

8

O'Byrne, Kenneth J., Halmos, G., Pinski, J., Groot, K., Szepeshazi, K., Schally, A. V., et al. (1994) Somatostatin receptor expression in lung cancer. European Journal of Cancer Part A : General Topics, 30(11), pp. 1682-1687.

45

Khan, M. I., Cherukuri, A. K., Farrell, R., Maloney, M., O'Byrne, K., Noonan, N., et al. (1993) Endoscopic ampullectomy - a new approach to difficult cannulation. Irish Journal of Medical Science, 162(12), p. 527.

Export as	Atom RSS 1.0 RSS 2.0